Effect of policy and practice changes on oral anticoagulation use in North Carolina by Beadles, Christopher A.
 
 
EFFECT OF POLICY AND PRACTICE CHANGES ON ORAL ANTICOAGULATION USE IN 
NORTH CAROLINA 
 
 
Christopher Alan Beadles 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Health Policy and Management in Gillings School of Global Public Health.  
 
 
Chapel Hill 
2013 
 
 
 
                                                                                                       Approved by: 
Kristen Hassmiller Lich PhD 
                                                                                                       Morris Weinberger PhD 
                                                                                                       M. Alan Brookhart PhD 
                                                                                                       Anthony Viera MD, MPH 
                                                                                                       Sandra B. Greene DrPH
ii 
 
ABSTRACT 
CHRISTOPHER BEADLES: Effect of policy and practice changes on oral anticoagulation 
use in North Carolina 
(Under the direction of Kristen Hassmiller Lich) 
 
 Despite a long history of proven effectiveness, oral anticoagulation therapy 
(OAT) has been underused in medical practice so the full potential for stroke risk reduction 
has yet to be realized in everyday clinical settings. Several policy changes intended to 
improve care quality and change care delivery were recently established, but the effect of 
these policy changes on OAT use is unknown. The overall objective of this proposal is to 
estimate the effect of policy and practice changes on OAT use in real world clinical settings. 
This work: investigates the impact of The Joint Commission’s National Patient Safety Goals 
on the initiation of OAT in eligible AF patients (Aim 1); evaluates the effect of geographic, 
physician, facility and patient factors on OAT initiation and time to discontinuation for eligible 
AF patients (Aim 2); and investigates the effect of patient-centered medical homes (PCMH) 
on OAT initiation (Aim 3). The overall hypothesis of the work is that both National Patient 
Safety Goals and PCMHs are associated with increased use of OAT, but only PCMHs are 
associated with greater time to OAT discontinuation.  
  Claims data from the North Carolina State Health Plan are used to create 
cohorts of incident AF before and after policy changes. Difference in difference regression 
modeling is utilized to evaluate OAT initiation upon hospital discharge in the cohorts before 
and after The Joint Commission policy changes. A survival analysis approach is employed
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 using Cox proportional hazard regressions to evaluate time to OAT discontinuation before 
and after these policy changes. A difference in difference modeling approach is used to 
compare OAT initiation by PCMH exposure status.  
 This research is significant in several respects: 1) it  examines an 
understudied area of health policy governing health care delivery safety and quality in a 
population with documented underuse of appropriate therapy; 2) it identifies and 
differentiates specific populations who have benefitted from policy and practice changes 
enabling targeted future interventions for maximum effect; and 3) it evaluates an innovation 
in the health care delivery model for primary care, the PCMH,  by providing evidence of its 
impact on guideline adherence in receiving OAT.  
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CHAPTER 1 
OVERALL BACKGROUND AND SIGNIFICANCE 
The Burden of Atrial Fibrillation  
  Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 
and 6.1 million Americans, and a major independent risk factor for stroke [1]. The lifetime 
risk for developing AF is 1 in 4 for men and women age 40 years and older [2]. In 
observational cohort studies, documented AF clearly precedes stroke in patients with an 
initial stroke event [3]. Patients with AF have a five-fold greater risk of stroke even after 
adjusting for other stroke risk factors [1]. Moreover, strokes secondary to AF are nearly twice 
as likely to be fatal as non-AF caused stroke, more likely to recur within one year, and result 
in greater severity of functional deficits among survivors [4,5]. The increased severity is 
independent of advanced age and other stroke risk factors [6]. AF is often asymptomatic 
[7,8] and frequently clinically undetected [9], thus the true risk of stroke related to AF is likely 
underestimated [10].  
  Stroke is associated with substantial health care costs, long term disability and is the 
4th leading cause of death in the US [1]. The annual direct cost of stroke in the United States 
in 2009 was an estimated $22.8 billion (total direct and indirect costs of $38.6 billion) [1] and 
the long-term cost of a single major ischemic event is an estimated $145,251 [11]. Following 
a first event stroke, one year mortality is approximately 25%, while 5-year mortality is greater 
than 50% [1]. While AF is directly responsible for 15-20% of strokes [12], direct annual costs 
of AF reflect more than just the cost of stroke care and are estimated at $6.6 billion [13]. 
Analysis of administrative claims data reveal that after an AF diagnosis, patient health care
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costs are 3 times greater than before an AF diagnosis, and for those who experience a 
subsequent transient ischemic attack, ischemic stroke or major bleed, post-event total direct 
costs increase 4-8 times pre-AF costs [14]. 
 While the overall prevalence of AF is roughly 1-2% among adults 20 years or older, it 
increases dramatically from 50 years of age (0.1%) to 80 years of age (10%) [15]. Applying 
the current prevalence of AF to US Census Bureau projections for the year 2050, the 
number of individuals with AF is expected to reach 12 million secondary to the larger 
proportion of elderly individuals [2].  
Oral Anticoagulation Therapy Efficacy, Effectiveness and Utilization 
Clinically, AF allows blood to pool in the small chambers of a patient’s heart (atria). 
This pooling of blood fosters a favorable environment for the coagulation of blood and 
formation of blood clots. In time, the blood clots dislodge or fragment blocking the arteries 
that supply the brain, resulting in an ischemic stroke. Warfarin decreases the blood’s ability 
to form clots and has been the primary anticoagulant in oral anticoagulation therapy (OAT) 
for nearly six decades. Beginning in the early 1990’s multiple randomized controlled trials 
confirmed the efficacy of Warfarin in reducing stroke risk secondary to AF and its superior 
stroke risk reduction to the anti-platelet agent acetylsalicylic acid (ASA) or aspirin (Table 1). 
Multiple meta-analyses have confirmed the results of individual trials [16-18]. Oral 
anticoagulation with Warfarin reduces the relative risk of stroke secondary to AF by 64% 
compared to placebo, while ASA reduces the relative risk by 22% compared to placebo [18].  
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Table 1. Stroke Prevention Trials using Antithrombotics in Atrial Fibrillation 
Study Year Participants Intervention Arms 
AFASAK  1989 1007 Warfarin*, aspirin and placebo 
BAATAF 1990 420 Warfarin* and control 
SPAF I 1991 1330 Warfarin*, aspirin* and placebo 
CAFA 1991 378 Warfarin and placebo 
SPINAF 1992 571 Warfarin* and placebo 
EAFT 1993 1007 Warfarin*, aspirin and placebo 
SPAF II 1994 1100 Warfarin and aspirin 
SPAF III 1996 1044 Warfarin* and low-dose Warfarin plus aspirin 
ACTIVE-W 2006 6706 Warfarin* and clopidogrel plus aspirin 
* Indicates a statistically significant result reported for efficacy 
ACTIVE-W: Atrial Fibrillation Clopidogrel Trial with Warfarin  AFASAK: Atrial Fibrillation, Aspirin, Anticoagulation  BAATAF: 
Boston Area Anticoagulation Trial for Atrial Fibrillation  CAFA: Canadian Atrial Fibrillation Anticoagulation  EAFT: European 
Atrial Fibrillation Trial  SPAF: Stroke Prevention in Atrial Fibrillation  SPINAF: Stroke Prevention in Non-rheumatic Atrial 
Fibrillation 
 
Observational studies confirm stroke risk reduction but at a smaller effect size. An 
early prospective observational study in two practice settings in Montreal followed 221 
patients with documented AF for a mean of 27 months [19]. The study reported a relative 
risk reduction in stroke for patients in the Warfarin treatment arm that was equivalent to the 
randomized trials, despite having patients that were older and sicker than those included in 
the trials. Go and colleagues found a 51% relative risk reduction associated with Warfarin 
use for an assembled cohort of 11,526 AF patients (July 1996-Jan 1997) followed for 25,341 
person-years in a large integrated health care system in Northern California [20]. Darkow 
and associates utilized a large claims database from a managed care organization to create 
a cohort of 12,539 patients with incident AF in the 2000 calendar year, of which 
approximately 40% received Warfarin while the remainder were Warfarin candidates [21]. 
After adjusting for age, gender and other stroke risk factors they observed a 22% relative 
risk reduction for patients receiving Warfarin during a maximum 720-day follow-up.  
In contrast, a similarly designed study of a large commercial health plan with 6.4 
million members identified a cohort of 6,764 incident AF patients from January 1998 to 
December 2000, in which 52% were exposed to Warfarin. Following adjustment for baseline 
characteristics, the study found no benefit of Warfarin in reducing intracranial ischemic 
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events [22]. Birman-Deych and associates studied a cohort of Medicare beneficiaries with 
AF who were hospitalized between March 1998 and April 1999 in all 50 states. After 
adjusting for comorbid conditions, Warfarin prescription was associated with a 35% relative 
risk reduction in ischemic strokes, but this effect was smaller in black and Hispanic 
beneficiaries [23]. A similar finding has been reported in Medicaid participants as well. 
Boulanger and associates created a retrospective cohort from administrative claims data in 
California Medicaid recipients aged 50 years and older. They identified 4,355 patients with 
incident AF between January 1998 and March 2002 in which 59% filled any prescription for 
Warfarin and Warfarin exposure occurred during only 37% of days following diagnosis. The 
relative risk reduction of stroke during periods of Warfarin exposure was 27% less than 
during periods of Warfarin non-exposure [24]. 
Effectiveness of OAT in reducing stroke risk in clinical practice is lower than that 
achieved in randomized clinical trials for several reasons. To achieve the same results as 
clinical trials, an equivalent level of anticoagulation is required [25,26]. However, 
observational studies of patients hospitalized for stroke as well as other reasons who are 
receiving OAT are often sub-therapeutic at the time of admission [27,28]. Clinical trials are 
designed and funded to have sufficient resources to provide a high level of supervision that 
leads to greater OAT control, while community practice in addition to lacking resources 
encounters multiple barriers to OAT initiation and persistence [29]. Poor management of 
OAT and patient non-adherence results in less time spent within therapeutic range [30,31]. 
Less time spent within therapeutic range translates into reduced stroke risk reduction 
associated with OAT [32]. Finally elderly individuals have a greater net benefit from 
receiving OAT, yet in clinical practice are less likely to receive OAT [33,34]. Fewer 
individuals, who receive the greatest benefit, initiating OAT in clinical practice further 
minimizes the observed effect of OAT on stroke risk reduction.  
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Despite heterogeneous estimates of Warfarin effectiveness in stroke risk reduction in 
practice, observational studies have demonstrated a significant and consistent reduction in 
overall medical costs associated with Warfarin exposure. A retrospective observational 
cohort study using claims data from a large managed care organization identified a cohort of 
3,981 incident AF patients between January 2001 and June 2002 and followed them at least 
6 months. The researchers found a 200% increase in total direct health care costs from pre- 
to post-AF diagnosis. Interestingly, regardless of stroke risk, exposure to Warfarin was 
associated with an 18-29% decrease in costs [14]. A similar finding was recently 
demonstrated in Medicare beneficiaries. Mercaldi and colleagues analyzed claims data from 
the Medicare 5% sample, identifying 119,764 incident AF patients from 2004 to 2005 and 
compared Warfarin users to non-users for an average of 2.1 years follow-up. Individually, 
use of Warfarin therapy among patients with AF was independently associated with lower 
medical costs, averaging $9,836 per patient per year [35].  
The reported magnitude of benefit with Warfarin oral anticoagulation therapy in 
practice is generally favorable and recent cost studies also support OAT. One might expect 
utilization among eligible candidates to be high as well. However, many observational 
studies have found substantial underuse of OAT among eligible patients with AF [36].  
Olgilvie and colleagues provide a systematic review of observational studies examining AF 
and stroke prevention therapy. They identified 78 studies, of which 56 met inclusion criteria 
containing data from 1980 to 2007. They report on data from 2000 to 2007 showing that 
among moderate and high risk stroke patients 4-48% (median 18%) received no therapy, 
10-56% (median 30%) received antiplatelet therapy and 9-86% (median 52%) received 
Warfarin therapy [37]. In AF patients that are at moderate or high risk for stroke, Warfarin is 
the guideline recommended therapy. However, the data from studies reporting underuse of 
6 
 
OAT is becoming outdated and in all cases precedes the development of two major policy 
changes anticipated to meaningfully affect OAT use. 
   
Policy and Practice Changes in Oral Anticoagulation: the establishment of 
anticoagulation National Patient Safety Goals 
The Joint Commission is the nation's oldest and largest standards-setting and 
accrediting body in health care. Its primary purpose is to [38]: “continuously improve health 
care for the public, in collaboration with other stakeholders, by evaluating health care 
organizations and inspiring them to excel in providing safe and effective care of the highest 
quality and value.” To this end, the Joint Commission evaluates and accredits more than 
19,000 health care organizations and programs in the United States. Joint Commission 
accreditation is required for reimbursement from Medicare and many private health 
insurance companies. The Joint Commission established its National Patient Safety Goals 
(NPSGs) program in 2002 to help accredited organizations address particular areas of 
concern in regards to patient safety [38]. The first set of NPSGs became effective January 1, 
2003 [38]. The NPSGs concerning anticoagulation were added in 2007 and became 
effective January 1, 2008 [38]. These goals were intended to increase the rate of guideline 
concordant care concerning OAT among hospitals providing anticoagulation services. 
Presumably the goals improve OAT utilization through a direct effect on hospitals and an 
indirect effect on patient adherence to OAT. The direct effect is a result of a hospital 
implementing a policy, guidelines, or anticoagulation management services in response to 
establishment of the NPSGs. The indirect effect may be mediated through a greater 
availability of OAT management resources, once it has been initiated [29,39].    
To my knowledge, the effect of The Joint Commission’s revision of the NPSGs has 
not been evaluated. However, literature examining the relationship between adoption of The 
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Joint Commission process of care guidelines and improved outcomes yields mixed results. 
For example, VanSuch and colleagues [40] found compliance with The Joint Commission 
guidelines for discharge instructions in heart failure patients was associated with decreased 
readmission rates and Kfoury and associates [41] reported a positive incremental 
relationship between degree of adherence to The Joint Commission core measures for heart 
failure and one-year survival. But Fonarow’s group [42] reported no association with 
adherence to The Joint Commission heart failure core measures and 60-90 day mortality or 
readmission; and Patterson and colleagues [43] found compliance with The Joint 
Commission heart failure core measures had no association with one year mortality or 
readmission.  
The contribution of this research is expected to provide a greater understanding of 
the effect of The Joint Commission NPSGs concerning anticoagulation on guideline 
concordant use of OAT with a specific focus on initiation and time to discontinuation. This 
contribution is significant because it examines an understudied area of health policy, The 
Joint Commission NPSGs that govern health care delivery in a population with documented 
underutilization of appropriate therapy. The study addresses a relevant policy intervention 
intended to modify organization of health care systems, delivery of health care services, and 
utilization with the intent to improve health care outcomes and cost-effectiveness. 
Understanding the effect of policy interventions such as The Joint Commission NPSGs on 
advancing health care safety, quality and efficiency will provide a baseline for evaluating 
future interventions aimed at improving America’s healthcare system.  
Policy and Practice Changes in Oral Anticoagulation: the emergence of the Patient 
Centered Medical Home 
Although the concept of a medical home originated in the pediatric population for 
children with special health care needs in 1967, the patient-centered medical home (PCMH) 
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that adopts many aspects of Wagner’s chronic care model [44] at first glance appears 
relatively novel [45]. Kilo and Wasson provide a brief yet remarkably clear summative history 
of forces that have lead to rapid and accelerating interest in PCMH model. They describe 
three phases of the PCMH development: 1) basic investigation (1970-1997) 2) model 
development (1997-mid-2000s) and 3) model dissemination (mid-2000s-present). A merging 
of various political and economic forces served to intensify attention on the PCMH model 
[45]. The current PCMH concept generally follows seven principles (see Text Box 1) outlined 
in the Joint Principles of the PCMH [46,47]. The PCMH is intended to re-center the US 
health care delivery system while improving quality and reducing health care costs [48-50].  
 
Since 2007 PCMHs have steadily increased in number nationally (Figure 1) [51]. 
This research effort represents a timely evaluation of a model of health care delivery that is 
being rapidly disseminated with substantial national policy ramifications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Text Box 1. Joint Principles of the Patient Centered Medical Home 
1. A personal physician 
2. Physician directed medical practice 
3. A whole-person orientation 
4. Provides coordinated and/or integrated care 
5. Committed to continuous evaluation/ improvement of care quality and patient safety 
6. Provides enhanced access to care 
7. Provides an enhanced payment structure 
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Figure 1. Growth of NCQA Accredited PCMHs and Participating Clinicians in the 
United States 
 
Substantial evidence exists supporting the effectiveness of several individual 
components of the PCMH. Rosenthal reviews much of the previous literature supporting 
these components [52]. For example, literature supporting the benefits of a personal 
physician includes: better patient health process measures and health outcomes for those 
with a continuous longitudinal relationship with a primary care provider; improved cancer 
screening; greater vaccination rates and reduced emergency department expenditures [52]. 
Rosenthal also reviews the literature supporting team directed practice, a whole-person 
patient orientation, coordinated care across all domains of a health care system, quality and 
safety, and finally enhanced access. Each individual component does appear to have solid 
grounding in the literature. However, little evidence exists today concerning the ability of 
PCMHs to improve quality, improve health outcomes and reduce costs [53,54]. Early 
evaluations of PCMHs typically included programs that adopted one or two components of 
the PCMH. An early review of the evidence on the PCMH model by Homer and colleagues 
found that that only 1 of the 33 studies reviewed was of an intervention modeled after the 
PCMH while the others tested only selected components [55]. Two other early papers 
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reviewed the literature on individual components of the medical home such as team-based 
care, rather than reviewing multi-component interventions that more closely resemble the 
PCMH model [56,57].  While several systematic reviews have been published providing 
support for the PCMH model, each has potentially troubling limitations. Three did not 
consider the rigor of the evidence in the studies reviewed [49,57,58]. Two reviews 
conducted a limited assessment selecting comparison group studies and peer-reviewed 
studies, respectively [55,59]. Neither of these considered the studies’ strength of the 
analytical methods or excluded studies lacking rigorous methods from evidence synthesis 
steps. 
Peikes et al. conducted a large systematic review of the evidence for the PCMH 
model through September 2010 [53]. They found that most interventions cited in the 
literature were actually precursors to the PCMH model and tested simply the addition of a 
care manager operating within a primary care practice. They also found that less than half of 
evaluations studied all three outcomes of cost, quality and access. Limiting the inclusion of 
studies to those that described interventions containing at least 3 of 5 principles of the 
PCMH model and utilized rigorous analytic methods generated 14 evaluations of 12 
interventions. The evidence from these studies indicates; some favorable effects on quality, 
patient experience, and caregiver experience; a few unfavorable effects on costs; and 
mostly inconclusive results. The authors conclude that stronger well-designed, well -
implemented evaluations of the full PCMH model are required to provide needed evidence 
and guide decisions regarding this promising but unproven model of care delivery. A more 
recent systematic review by Jackson et al. compared 19 studies of PCMH interventions and 
found a small positive effect on patient experience and small to moderate positive effects on 
the delivery of preventive care, but limited evidence in reduction of emergency room visits or 
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hospital admissions and no evidence for cost savings [54]. Jackson et al. have found 
essentially identical results in their more recent review as well [54]. 
PCMHs may have a beneficial effect on OAT initiation and persistence through 
several mechanisms which include: a stronger therapeutic relationship with a personal 
physician; enhanced access to care (ex: obtaining prescription refills, laboratory collections); 
greater follow-up and monitoring (ex: laboratory values, unfilled prescriptions); coordination 
of care with specialists (ex: cardiologists); and a practice commitment to improving quality 
and patient safety. As described above, these mechanisms are individually supported in the 
literature but have not been well demonstrated as part of a multi-component intervention.  
The specific barriers and principles of the PCMH that address these barriers are 
summarized in Table 2.  
Table 2. Barriers to OAT Initiation Addressed by Principles of the PCMH 
 
Of particular interest to anticoagulation, some PCMHs accredited by the National 
Committee on Quality Assurance choose to also pursue a Heart Stroke Recognition 
Program. This program contains an audit of the practice’s use of guideline appropriate 
antithrombotics as a criterion for the recognition. This raises awareness concerning practice 
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norms and performance in providing guideline concordant care in AF patients with moderate 
or high stroke risk. The audit-feedback intervention has been consistently shown to have an 
effect on provider behavior in health care delivery [60].  
  This research contributes to existing literature through examining processes of care 
and disease specific outcomes in a variety of independent PCMHs. This contribution is 
significant because it implements a rigorous evaluation of the PCMH model while providing 
much needed evidence concerning the effect of receiving care within an accredited PCMH 
on guideline concordant care in OAT initiation and time to OAT discontinuation.   
 
 
Policy and Practice Changes in Oral Anticoagulation: Interactions with patient-, 
physician- , and facility-level factors 
As alluded to above, several hypothesized types of factors serve as barriers to OAT 
initiation. Patient factors, physician factors and facility factors have each been reported as 
determinants of receiving OAT among AF patients [23,61-64,29,39]. However, these three 
categories of factors have not been studied since establishment of NPSGs or PCMHs and 
have not been studied in combination with each other. Studying patient, provider and 
system factors in combination following these policy changes reflects a more realistic clinical 
practice scenario. Additionally, while the role of these factors on prevalent use of OAT 
among AF patients has been reported, these factors have not been evaluated in the context 
of initiation and time to discontinuation of OAT among a cohort of incident AF patients. 
Existing work primarily emphasizes barriers to OAT initiation. However, for most patients 
with AF at moderate or high risk for ischemic stroke, the indication for OAT is long-term, or 
life-long. The risk of stroke, does not decline with time, rather it increases, and substantially. 
Thus, it is crucial to raise awareness concerning persistence, or time to discontinuation of 
OAT in clinical practice. I aim to expand current thinking in anticoagulation treatment beyond 
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prevalent OAT use among AF patients to a greater awareness of two distinct and equally 
important processes: initiation and time to discontinuation. These processes will more 
accurately define aspects of OAT use than has been done in prior research. A more precise 
understanding of factors influencing both OAT initiation and time to OAT discontinuation will 
assist in identifying additional specific intervention targets to increase OAT use and enhance 
effectiveness in clinical settings. 
Evaluating the interplay of patient, physician and facility factors allows me to 
examine the degree of uniformity or lack of uniformity in the effect of policy changes on OAT 
initiation and time to OAT discontinuation. Population groups at highest risk for stroke or at 
highest risk for not receiving OAT may experience a disproportionately small increase in 
appropriate OAT initiation compared to other population groups. This research contributes to 
existing knowledge concerning variation in OAT initiation and time to discontinuation, and 
evaluates the impact of anticoagulation policy change as it relates to two specific aspects of 
OAT utilization. This contribution is significant because it identifies and differentiates specific 
populations who have benefitted from the policy change and thereby aids in targeting future 
interventions.  
 
Conceptual Framework 
 The research questions and subsequent hypotheses in this proposal draw support 
from a conceptual framework that is an adaptation of Andersen’s behavioral model of health 
services use and his subsequent revisions to the original framework [65]. As illustrated in 
Figure 2, the framework considers the two policy changes (National Patient Safety Goals 
and patient-centered medical homes) as part of the external environment. The external 
environment, which includes physical, political and economic components, such as a 
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healthcare system influence an individual’s use of health services and subsequently their 
likelihood of receiving appropriate treatment and continuing treatment. While not explicitly 
shown below, dynamic feedback loops also affect the external environment and other 
predisposing factors, such as age, gender, and insurance status of the population.  
Figure 2. External Environment Changes & Their Effects on OAT Use & Persistence 
 
For instance a hospital with an academic affiliation may be more likely to provide 
onsite outpatient anticoagulation management services in a dedicated anticoagulation clinic. 
A hospital with an academic affiliation may also have greater capacity for patient follow-up 
via the use of an electronic health record and additional staff resources. This greater patient 
follow-up capacity translates into a more efficient system of monitoring and reinforcing 
adherence to prescribed treatment regimens. The hospital’s urban or rural location 
influences both the level of patient access to hospital-provided outpatient services and the 
strength of association with academic institutions. While hospital size is not thought to 
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strongly influence patient access to services, it is associated with location, academic 
affiliation and overall capacity to provide requisite patient follow-up.  
Similarly the effect of changes in the external environment would be anticipated to 
affect health care systems differently according to their inherent characteristics. A large 
academic hospital in an urban setting previously providing anticoagulation management 
services in an anticoagulation clinic might logically have a well developed anticoagulation 
policy when the NPSGs became effective. This hospital would be relatively unaffected by 
the change in the external environment. However, a small or medium size hospital without 
academic affiliation, and lacking well developed anticoagulation management services or 
internal anticoagulation policies, may be substantially affected by establishment of the 
NPSGs. Hospitals that are significantly affected by policy changes in the external 
environment are also more likely to modify or alter hospital practice norms. 
Specific Aims 
The work of this proposal is summarized in the following specific aims and tests 
hypotheses that follow from reflecting on the conceptual model in Figure 1 and evidence 
published in the peer-reviewed literature grounding the model in OAT initiation and time to 
discontinuation: 
Aim 1: To investigate the effect of The Joint Commission National Patient Safety 
Goals on OAT initiation in eligible AF patients. 
 
Hypothesis: Establishment of The Joint Commission National Patient Safety Goals has led 
to increased initiation of OAT among eligible patients.   
I utilize claims data from the North Carolina State Health Plan to create a longitudinal cohort 
of individuals diagnosed with AF from 2006-2010; the cohort will be split into pre- (January 
2006-December 2008) and post- (January 2009-December 2010) intervention periods. 
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Using novel control groups (e.g. mechanical heart valve patients with high stroke risk, and 
paroxysmal AF patients with minimal stroke risk) I use difference in difference regression 
models to compare OAT initiation following hospital discharge before and after policy 
changes.  
Aim 2: To evaluate the effect of geographic, physician, facility and patient factors on 
OAT initiation and discontinuation. 
Hypothesis: Rural status, health professional shortage areas, outpatient diagnosis, 
increasing number comorbid chronic conditions, and increasing patient age are negatively 
associated with initiation and long term persistence of OAT. 
Using the previously defined cohort, difference in difference regression modeling is used to 
estimate the effect of these factors on OAT initiation. Survival analysis using Cox 
proportional hazards regressions is used to estimate the effect of these factors on time to 
OAT discontinuation.  
Aim 3: To investigate the effect of exposure to a Patient-Centered Medical Home on 
OAT initiation. 
 
Hypothesis: Receipt of care in a National Committee on Quality Assurance accredited 
Patient Centered Medical Home among eligible atrial fibrillation patients is directly 
associated with OAT initiation. 
Inverse probability of treatment weights combined with generalized estimating equations are 
used to compare OAT initiation among those exposed to an accredited PCMH to those 
unexposed.  
 
 
Chapter 2 
THE EFFECT OF NATIONAL PATIENT SAFETY GOALS ON INITIATION OF ORAL 
ANTICOAGULATION THERAPY 
 
Overview 
To examine the effect of The Joint Commission’s National Patient Safety Goals 
(NPSGs) on initiation of oral anticoagulation therapy for individuals with incident atrial 
fibrillation. Our data source is the North Carolina State Health Plan claims data from 
944,500 individuals enrolled between January 1, 2006 and December 31, 2010, 
supplemented with data from the Area Resource File and Online Survey, Certification and 
Reporting data network. We utilize a retrospective cohort new user design with two control 
groups: guideline positive—patients at very high risk of thromboembolism (mechanical heart 
valve and pulmonary embolism); guideline negative—patients at very low risk of 
thromboembolism. We test for changes in oral anticoagulation therapy initiation following 
revision of NPSGs to include anticoagulation. We developed multivariate models using 
difference-in-difference estimates with control variables defined a priori. Effects were 
estimated with generalized estimating equations. Following revision of NPSGs to include 
anticoagulation, eligible individuals with incident atrial fibrillation exhibited an 11 percentage 
point increase in oral anticoagulation therapy initiation (SE=3.6; p<.01). NPSGs for 
anticoagulation resulted in greater initiation of guideline concordant oral anticoagulation 
therapy for eligible individuals with incident atrial fibrillation. 
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Introduction 
Oral anticoagulation therapy (OAT) to reduce acute ischemic stroke risk in moderate 
or high risk atrial fibrillation (AF) patients, typically with Warfarin, has been recommended by 
guidelines from major organizations for nearly two decades [66]. However, despite its 
benefit, OAT is often underutilized among eligible AF patients 
[63,67,25,27,28,68,69,29,70,71,21-23,72,73,61,74-76]. Reasons for underutilization of this 
therapy are attributed to patients and physicians; however, health care systems also play a 
role [71,72,77-79,39,80].  
The Joint Commission is the nation's oldest and largest standards-setting and 
accrediting body in health care. Its primary purpose is to [38]: “continuously improve health 
care for the public, in collaboration with other stakeholders, by evaluating health care 
organizations and inspiring them to excel in providing safe and effective care of the highest 
quality and value.” To this end, the Joint Commission evaluates and accredits more than 
19,000 health care organizations and programs in the United States. Joint Commission 
accreditation is required for reimbursement from Medicare and many private health 
insurance companies. The Joint Commission established a National Patient Safety Goals 
(NPSGs) program in 2002 to help accredited organizations address specific concerns 
regarding patient safety. To this end, they established the Patient Safety Advisory Group, a 
panel of nurses, physicians, pharmacists, risk managers, clinical engineers and other 
professionals who have hands-on experience in addressing patient safety issues in a wide 
variety of health care settings.  This panel continuously evaluates and updates NPSGs to 
identify, prioritize, and help address a broad range of emerging patient safety issues. In 
2008, the NPSGs were updated to include goals regarding OAT. 
             The NPSGs concerning anticoagulation (NPSG 03.05.01) represent a change in the 
external environment intended to affect the health care system, most notably hospitals. They 
do not mandate that all eligible patients receive anticoagulation, but rather provide explicit 
19 
 
guidelines and expectations for hospitals that provide anticoagulant therapy and/or long-
term anticoagulation prophylaxis to reduce the likelihood of patient harm associated with 
these therapies. Achieving compliance with NSPGs may be moderated by a hospital’s 
preexisting resources and practice norms, as well as their willingness to invest in the 
infrastructure required to meet them.  Hospitals with sufficient resources may be in 
compliance with regulatory requirements before or soon after they are established. Hospitals 
with fewer resources may take longer to become compliant with new regulatory 
requirements. In the case of OAT, hospitals may invest in resources to provide long term 
out-patient management and monitoring for patients receiving OAT, for example, 
anticoagulation clinics. Providing anti-coagulation clinics may have an indirect effect on 
hospital performance, as community physicians with admitting privileges in these hospitals 
may be more likely to initiate OAT for eligible patients because of both hospital regulatory 
requirements and additional resources to manage and monitor anti-coagulation [29,39].    
 Implementation of NPSGs, in general, was intended to substantially impact the 
health care quality (especially process-oriented measures) in organizations they accredit. 
However, results for various other Joint Commission initiatives have been mixed. For 
example, compliance with Joint Commission guidelines for discharge instructions in heart 
failure patients was associated with decreased readmission rates [40], and there was a 
positive relationship between adherence to The Joint Commission heart failure core 
measures and one-year survival [41]. However, other studies found no association between 
adherence to Joint Commission heart failure core measures and 60-90 day mortality or 
readmission [42] or with mortality or readmission at one year [43].  
We sought to determine the effect of The Joint Commission’s NPSGs for 
anticoagulation on OAT initiation. We hypothesized the NPSG were associated with 
increased initiation of OAT among eligible patients hospitalized with incident AF. Our 
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primary analysis examines a potential direct effect of the NPSGs while a set of sensitivity 
analyses examine potential indirect effects of the NPSGs.   
 
Methods 
Data Sources 
We used data from January 1, 2006-Deceember 31, 2010 from the North Carolina 
State Health Plan (NCSHP), a large self-funded insurance plan for the study. The NCSHP, 
administered by Blue Cross and Blue Shield of North Carolina, includes almost 1 million 
state employees, teachers, retirees and their dependents. Approximately 10% of enrollees 
are retired non-Medicare participants, and 16% of enrollees are retired Medicare 
beneficiaries. This claims structured database contains inpatient, outpatient and pharmacy 
records. Enrollee descriptors include unique encrypted member identification numbers, 
basic demographic information including age, gender, county, and zip code of primary 
residence. Records include information about diagnoses, procedures, providers, charges 
and payments. The database also contains physician level characteristics which include 
provider zip code, type of provider and provider specialty if applicable. We linked hospital 
facility characteristics to the database, including accreditation as a primary stroke center, 
hospital bed size, and participation in a stroke quality improvement program. Finally we 
linked individual and facility counties with additional variables from the Area Resource File 
providing a unique opportunity to concurrently analyze health care delivery at multiple levels 
including: individual patient characteristics, provider characteristics, and hospital facility 
characteristics.  
 
Study Sample 
We created three cohorts of patients: (1) new onset AF patients; (2) guideline 
positive controls, which includes patients at very high risk of thromboembolism (mechanical 
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heart valve and pulmonary embolism); and (3) guideline negative controls, that is patients 
with a very low risk of thromboembolism (paroxysmal atrial fibrillation). For all three cohorts, 
patients needed to be continuously enrolled in the NCSHP a minimum of 6 months prior to 
the qualifying index claim and a minimum of 6 months following the qualifying index claim. 
Individuals with a prescription claim for Warfarin more than 30 days prior to an index claim 
for any of the three cohorts (i.e. AF, mechanical heart valve, paroxysmal AF) were excluded 
from the sample due to a high probability of representing prevalent rather than incident 
conditions.  Figure one provides a summary of cohort identification and determination of 
eligibility. Eligibility criteria for each cohort are described below. 
New onset AF patients:  We used either one inpatient diagnosis or two outpatient 
diagnoses within 12 months (International Classification of Disease 9th edition-Clinical 
Modification (ICD-9-CM) code 427.31) to identify individuals with AF. We designated the first 
outpatient AF claim or the date of admission for an inpatient claim as the date of entry into 
the cohort. The American College of Cardiology, The American College of Chest Physicians 
and the American Heart Association endorse the use of a risk based score to identify 
individuals who will benefit from receiving OAT. CHADS2 is a commonly employed scoring 
system [81]. Individuals receive 1 point for congestive heart failure, hypertension, age 
greater than 75 years, diabetes mellitus and receive 2 points for any prior stroke or stroke 
symptoms. It is recommended that an individual with a score of 2 or more should receive 
OAT. This score is readily generated using claims data and was used to identify individuals 
with new onset AF who should receive OAT (See Appendix Table 2.1 for ICD-9-CM codes 
for these diagnoses). We included all individuals meeting criteria for incident AF with a 
CHADS2 score > 2. While there are very few absolute contraindications to receiving OAT, 
numerous relative contraindications exist. To increase the precision of our estimates we 
excluded individuals with one or more relative contraindications to receiving OAT (identified 
using ICD-9-CM codes) from the incident AF or intervention cohort (See Appendix Table 2.2 
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for contraindications and ICD-9-CM codes).  Finally, to reduce the probability of including 
individuals with prevalent AF rather than incident AF we excluded individuals with any AF 
related claim in the six months preceding the index claim.    
Guideline positive controls: Individuals with either one inpatient diagnosis or two 
outpatient diagnoses within 12 months indicating a mechanical heart valve or significant 
thromboembolism with at least six months of continuous eligibility prior to and six months 
continuous eligibility following the index claim were included in the guideline positive cohort 
(See Appendix Table 2.3 for diagnoses and ICD-9-CM codes). The CHADS2 score was not 
applied to this cohort, as it is only validated in patients with AF. Finally, to reduce the 
probability of including individuals with prevalent conditions rather than incident mechanical 
heart valves or significant thromboembolism we excluded individuals with any condition 
related claim in the six months preceding the index claim. 
Guideline negative controls: Individuals with either one inpatient diagnosis or two 
outpatient diagnoses within 12 months for paroxysmal AF (ICD-9-CM code 427.21) with at 
least six months of continuous eligibility prior to and six months continuous eligibility 
following the index claim were included in the guideline negative cohort. Figure 2 provides a 
visual summary of the initial sample and final cohort size for each group. 
Measures 
The primary dependent variable is OAT initiation, a binary outcome defined as 
having a prescription drug claim for Warfarin within 30 days of the index claim. Index claims 
occurring in years 2006-2008 were assigned pre-NPSGs status while index claims occurring 
in 2009-2010 were assigned post-NPSGs status. The key explanatory variable is the 
interaction term between a binary indicator for pre/post status of The Joint Commission’s 
NPSGs and a binary indicator variable for the incident AF cohort, which represents the 
difference in difference estimator.  
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Control variables were created at the patient level and facility level. All control 
variables were identified a priori and measured in the baseline period or immediately prior to 
the index AF claim to mitigate potential confounding. Patient level control variables include 
age, gender, Charlson Comorbidity Index, CHADS2 score, rural/urban residence, and 
number of outpatient visits to a primary care provider in the 30 days prior to the index claim. 
Charlson Comorbidity Index was categorized as 0, 1-2, and 3 or more. CHADS2 score was 
categorized as 2, 3-4, and 5 or more. Rural/Urban status was categorized as metropolitan, 
micropolitan or rural as defined by the Area Resource File [82].  
Facility level control variables include a binary variable indicating hospital primary 
stroke center accreditation status (as defined by CMS) for each time period, a binary 
variable indicating participation in an acute stroke care quality improvement program (Get 
With the Guidelines Stroke or North Carolina Stroke Care Collaborative) for each time 
period, distance of hospital from enrollee residence, hospital bed size and rural/urban facility 
location. Get with the Guidelines Stroke participation was determined from the American 
Heart Association website (www.heart.org). Participation in the North Carolina Stroke Care 
Collaborative was provided by the organization.   We calculated distance as a function of 
straight line distance from the centroid of patient and hospital zip codes using SAS 9.2. 
Hospital bed size was determined from the Online Survey, Certification and Reporting 
(OSCAR) data network maintained by the Centers for Medicare and Medicaid Services.  
 
Statistical Analysis 
We examined cohorts for differences in baseline covariates as well as differences 
within cohorts between pre and post time periods. Unadjusted rates of oat initiation for each 
cohort were also examined. We then estimated the relationship between NPSG and 
initiation of OAT among individuals with new onset AF using a difference in difference 
approach and multivariable regression equations. Differences in OAT initiation before and 
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after the policy change for the comparison group are attributed to a time effect. Subtracting 
this difference from the difference in the AF cohort yields an estimate that is more robust to 
external factors and time effects. In practice the difference in difference estimate is created 
by interacting the treatment (in this case time) variable with a dummy variable indicating the 
treatment cohort.  
Pr(OATift=1|Xift) = Xβ where f(E[Y]) = Xβ and var(E[Y])=g(E[Y])                  (Eqn 1) 
with Xβ = β0 + β1AFi + β2Posti + β3(AFi*Posti) + β4Xi + e  
where i indicates the individual. OAT is the outcome variable as defined above. AF 
represents the cohort and Post indicates whether the index claim occurred pre (Post=0) or 
post (Post=1) NPSG development. X is a vector of individual patient and facility control 
variables defined above. Facility level fixed effects are taken into account by clustering 
within facilities and specifying an exchangeable within-group correlation structure. The 
coefficient that identifies the effect of interest is β3, which estimates the effect of NPSG on 
the probability of OAT initiation for patients with incident AF.    
 We utilized a generalized estimating equation model with a Poisson distribution, log 
link (denoted by f(E[Y]) above) and exchangeable within group correlation structure 
(denoted by var(E[Y]) above) to account for within hospital correlation. Robust standard 
errors were included to correct for underdispersion of the binary dependent variable in the 
context of a count distribution. While the exponentiated coefficients may be interpreted as 
risk ratios when using a log link, we converted the coefficients to average marginal effects 
as absolute risk differences for ease of interpretation. All models were estimated in Stata 11 
(StataCorp, College Station, TX). 
We conducted several sets of sensitivity analyses. The first assessed potential 
measurement error in the dependent variable, OAT initiation. The rise of many low-cost 
generic prescription drug programs administered through major retailers has caused 
concern regarding under identification of generic drugs within pharmacy claims data [83]. 
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Warfarin has been generic for several decades, and multiple generic formulations exist. 
While a claim for Warfarin is specific for OAT initiation, it may be lacking somewhat in 
sensitivity. We created two additional definitions for OAT initiation using claims for laboratory 
blood tests associated with blood coagulation or anticoagulation management claims. (See 
Appendix Table 2.4 for CPT codes and ICD-9-CM codes employed) The laboratory blood 
tests were hypothesized to represent a sensitive measure of OAT initiation that might have 
less specificity for OAT initiation as it is associated with the monitoring of the effect of 
Warfarin, but is not specific to anticoagulation management alone.  The first additional 
definition for OAT initiation combined either a pharmacy claim for Warfarin or a claim for 
associated laboratory blood tests or a claim for outpatient anticoagulation management. The 
second additional definition for OAT initiation excluded the pharmacy claim, utilizing only the 
laboratory blood test and outpatient anticoagulation management claims to define initiation. 
The next sensitivity analysis compared the effect of the policy on an inpatient only cohort, 
hypothesized to demonstrate the greatest effect, an outpatient only cohort, and a combined 
inpatient and outpatient cohort. The final set of sensitivity analyses involved an extensive 
evaluation of nonlinear effects of included model covariates and additional county level 
covariates that could be hypothesized to affect the observed relationship between the policy 
change and observed OAT initiation rates.         
The study protocol was approved by the University of North Carolina at Chapel Hill 
Institutional Review Board.  
 
Results 
Descriptive Findings 
 Baseline characteristics of the AF, guideline positive and guideline negative cohorts 
are presented in Table 3. While the cohorts differ from each other with respect to indication 
for OAT, they are relatively homogeneous between pre and post time periods. As expected, 
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OAT initiation was decidedly higher in the guideline positive cohort (67.5%) than in the 
intervention (26.8%) or guideline negative cohort (23.8%). Additionally, OAT initiation in the 
guideline negative cohort was higher than expected. OAT initiation in the intervention group 
(26.8%) was within range of previous observational studies [36]. Within specific indication 
cohorts, average age remained stable while number of diagnoses tended to increase in the 
post period. Overall number of relative contraindications for OAT did not change appreciably 
between pre and post periods. The number of outpatient claims from primary care 
physicians in the 30 days preceding entry into a cohort remained stable or marginally 
increased between the pre and post periods. Hospital characteristics are notable for a 
marked increase in the percentage of individuals treated in hospitals that were accredited 
primary stroke centers or participating in some form of quality improvement program for 
acute stroke care. This trend was observed in all cohorts. The percentage of individuals 
treated in rural and critical access hospitals increased marginally from the pre period to the 
post period. County level characteristics in general remained stable from the pre to post 
period. Two notable exceptions to this trend were average unemployment rate in the county 
and percent of persons in poverty in the county, which increased in all cohorts from the pre 
to post period. Consistent with unemployment rates and percent persons in poverty, median 
household income fell in the post period for all cohorts. The number of general practice 
providers and cardiovascular specialists remained stable or marginally increased in the post 
period for the intervention and guideline positive cohorts but decreased slightly for the 
guideline negative cohort. The county level race and ethnicity demographics remained 
stable across time for all cohorts.  
Regression Results 
The unadjusted bivariate results (top of Table 4) indicate that OAT initiation 
marginally decreased for the guideline positive and guideline negative cohorts while OAT 
initiation increased for the intervention cohort. The marginal effect for the interaction term 
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between the intervention cohort and the post period represents the difference in difference 
estimate. The OAT initiation rate increased on average 12 percentage points (p<0.001) for 
this cohort in the post period.  This increase in OAT initiation dropped slightly, but remained 
significant (11 percentage point increase, p<0.01) in multivariable models controlling for 
additional patient and hospital facility characteristics. While the difference in difference 
estimate for the guideline negative cohort suggested a decrease in OAT initiation, the 
marginal effect was small and insignificant. Oldest individuals (71+ years) were less likely to 
initiate OAT as were individuals with the highest number of co-morbid conditions. Higher 
CHADS2 scores, indicating greater risk of acute ischemic stroke were not associated with 
greater OAT initiation. Greater number of outpatient primary care physician claims preceding 
entry into the cohort was associated with increased OAT initiation. Finally, residential 
distance from the admitting hospital was negatively associated with OAT initiation.  
Sensitivity Test Results 
Results of sensitivity analyses are presented in Table 5. Overall, the difference in 
difference estimate for the intervention group was robust to alternate definitions of OAT 
initiation. The combined pharmacy claim, blood laboratory test, anticoagulation management 
definition of OAT initiation yielded a similar marginal effect of a 9 percentage point increase 
(p<0.05) in OAT initiation for the treatment group in the post period. The marginal effect was 
smaller and insignificant in the blood laboratory test and anticoagulation management only 
definition of OAT initiation. Other associations were similar to that observed in the primary 
analysis. We also found a strong marginal effect on OAT initiation for an outpatient only 
intervention cohort and the combined inpatient-outpatient cohort. Finally multiple model 
specifications with alternate functional form and additional control covariates resulted in 
similar findings as our primary analysis (See Appendix Table 2.5). 
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Discussion  
This study assessed the effect of the Joint Commission updating NPSG to include 
OAT on OAT initiation within a large privately insured population across North Carolina with 
new onset AF. The study has several unique strengths. First, the use of guideline positive 
and guideline negative control groups allow for greater mitigation of potential time bias 
between the pre and post periods. This overcomes a traditional deficit in observational 
studies. Second, the nature of this statewide claims database allows for analysis of a 
relatively stable population of privately insured state workers, spouses, dependents and 
retirees in a population of approximately one million, providing support for generalizing to 
other privately insured populations. A third strength of the study is the data linkages with the 
Area Resource File to provide a rich array of county level control variables and survey 
information from the OSCAR database to provide hospital facility variables. A fourth strength 
of the study is inclusion of multiple controls for co-morbid conditions and relative 
contraindications to OAT. Finally, the clustering of individuals within the hospital in which 
they received treatment mitigates potential effects of outlier hospitals on the population 
averaged effect of the policy change. 
We found a positive association between revision of NPSG by The Joint Commission 
to include OAT and OAT initiation for individuals with new onset AF, on average a 10 
percentage point increase in the rate of OAT initiation. The strong positive association 
between NPSG and the outpatient cohort in our sensitivity analysis suggest an indirect 
effect of NPSG as well. While our results suggest that OAT initiation decreased for 
individuals in whom OAT is not indicated (the guideline negative cohort), the effect size is 
small and insignificant. The rate of OAT initiation in the guideline positive cohort was smaller 
than anticipated, but remained relatively constant in pre and post periods; this supports our 
choice as a positive control which was relatively unaffected by the policy change. The 
negative association between age and OAT initiation as well as number of comorbidities and 
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OAT initiation are consistent with what has been previously described in the literature [84]. 
The relative lack of association of increasing CHADS2 scores and OAT initiation is also 
consistent with prior work [85].  
The relatively low OAT initiation in the guideline positive cohort and the intervention 
cohort, as well as the higher than expected OAT initiation in the guideline negative cohort, 
are interesting. However this finding may reflect the nature of health insurance claims data 
that represent imperfect information collected for purposes other than the observational 
study. Our measured rates of OAT initiation in the AF cohort are consistent with prior work in 
this area [36]. We are not aware of published OAT initiation rates for individuals with 
mechanical heart valves or significant thromboembolism. Using this group as a benchmark 
sheds new light on previous observational studies. Underutilization of OAT should be 
reported with caution given the inherent limitations of using claims data. We view our results, 
not as an indictment suggesting poor quality of care for new onset AF, but rather as an 
examination of positive trends in guideline concordant care following policy change.  
 There are several limitations of our study. First, because we used claims data, we 
may have misclassified OAT initiation.  This is especially true because the popularity of low-
cost generic prescription drug programs may lead to patients filling prescriptions for OAT 
without billing the insurer[83]. We do not have reason to suspect a differential error in 
pharmacy claims for Warfarin with respect to the three cohorts regarding OAT initiation. 
Furthermore, this trend, if present, may increase with time, which would bias OAT initiation 
downwards in the post period and may explain the slight decrease in OAT initiation among 
the guideline positive cohort.  Importantly, our sensitivity analyses suggested that findings 
were robust to alternative definitions of OAT initiation. Second, we could not control for 
individual level race, ethnicity or socioeconomic status. However, we controlled for county 
level indicators of race and socioeconomic status to mitigate these potential effects. Finally, 
our cohorts were predominantly individuals with employee sponsored group health 
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insurance and the results may not generalize to publicly insured populations. Notably, our 
cohorts included a large proportion of retired Medicare enrollees utilizing both their Medicare 
and NCSHP benefits, which serves to enhance generalizability to Medicare beneficiaries.  
Despite the noted limitations, our findings suggest that NPSG concerning 
anticoagulation resulted in greater initiation of oral anticoagulation therapy for eligible 
individuals with incident atrial fibrillation, increasing guideline concordant care in this 
population.  Finally we note that new medications for OAT were approved for reduction of 
stroke risk in patients with AF in late 2010. These agents do not require the same frequency 
of laboratory monitoring and titration of dosage as Warfarin. While more expensive than 
Warfarin, these new agents are anticipated to significantly reduce the burden of 
anticoagulation management for both patients and providers. OAT initiation may increase to 
a greater degree in years following 2010 that are unrelated to policy changes and rather 
determined by the availability of novel anticoagulation agents with less intensive monitoring 
requirements. Observational studies in the future may reveal OAT initiation practice patterns 
more concordant with guidelines in association with the availability of novel oral 
anticoagulants.     
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Figure 3. Selection of Incident AF, application of inclusion/exclusion criteria and 
identification of comorbid conditions 
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Figure 4. AF Cohort Sample Selection 
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Table 3. Baseline Characteristics Among Intervention Group and Control Groups 
Variable Pre Period Post Period 
 Eligible AF Mechanical 
Heart Valve 
(+ Control) 
Non-
eligible AF              
(- Control) 
Eligible AF Mechanical 
Heart Valve 
(+ Control) 
Non-eligible 
AF                 
(- Control) 
Sample Size 1,359 1,597 302 662 1,111 204 
OAT initiation 26.8 67.5 23.8 31.7 62.0 20.6 
Patient Characteristics 
 Age 77.9 (11.2) 65.0 (15.7) 71.2 (12.9) 76.7 (11.3) 65.4 (15.3) 70.6 (12.6) 
Male 40.5 41.3 53.3 38.7 40.8 57.4 
Rural 9.7 10.2 9.3 12.3 10.5 11.8 
CHF 29.7 18.8 32.5 23.0 27.1 34.3 
Hypertension 94.7 68.1 82.8 96.2 76.8 85.8 
Diabetes Mellitus 45.3 26.5 39.4 45.5 35.2 39.7 
Ischemic Stroke 23.7 18.8 21.5 35.5 31.1 29.4 
CHADS2 Score 2.9 (1.0) 1.8 (1.5) 2.4 (1.5) 3.0 (1.1)  2.3 (1.7) 2.6 (1.6) 
Charlson Index 2.0 (1.7) 1.4 (1.6) 2.3 (2.0) 2.1 (1.7) 1.9 (2.0) 2.7 (2.3) 
Hemorrhagic stroke 0 1.8 0.7 0 1.6 2 
GI bleed 0 4.1 2.0 0 8.5 5.4 
Falls Risk 0 7.5 8.9 0 13.8 7.4 
Cirrhosis 0 2.9 2 0 5.3 4.9 
Dementia 0 1.8 2.3 0 2.3 2.5 
Terminal Illness 0 7.4 6.3 0 7.5 6.9 
Relative OAT 
Contraindications  
 0* 0.5 
(0.7) 
0.4 
(0.7) 
 0* 0.7 
(0.9) 
0.6 
(0.9) 
Outpatient visits  3.1 (3.6) 4.1 (6.1) 4.0 (7.2) 3.5 (3.6) 4.8 (5.6) 4.0 (5.5) 
Facility Characteristics 
Rural Hospital 4.7 4.4 2.4 5.8 6.0 3.1 
Primary Stroke 
Center 
19.2 21.7 31.1 45.8 43.8 50.5 
Participates in 
GWTG 
48.6 50.5 47.4 59.2 56.3 63.7 
Hospital Bed Size 449 (311) 464 (309) 525 (322) 461 (307) 460 (310) 506 (324) 
Distance residence- 
hospital (miles) 
21.7 
(82.2) 
23.9 
(76.7) 
22.9 
(57.9) 
20.1 
(48.0) 
18.4 
(53.4) 
18.5 
(28.7) 
County Characteristics 
Percent White 68.9 (15.3) 68.3 (15.0) 68.5 (14.5) 68.5 (15.1) 68.7 (15.0) 67.6 (15.2) 
Percent Black 21.4 (13.2) 21.8 (13.2) 21.6 (12.6) 22.0 (13.3) 21.4 (13.3) 22.5 (14.2) 
Percent American 
Indian 
1.4 (5.2) 1.5 (5.2) 1.4 (4.8) 1.3 (4.7) 1.5 (5.1) 1.2 (2.0) 
Asian 2.0 (1.9) 2.2 (2.0) 2.2 (2.0) 1.9 (1.9) 2.1 (2.0) 2.2 (2.0) 
Hispanic 7.9 (3.6) 8.0 (3.7) 8.0 (3.3) 8.0 (3.7) 8.1 (3.6) 8.3 (4.4) 
General 
Practitioners 
62.6 (67.8) 68.1 (72.1) 73.5 (76.1) 68.4 (79.8) 73.5 (87.0) 73.6 (80.9) 
CV specialists 17.0 (21.6) 18.6 (22.9) 20.7 (24.2) 17.6 (23.2) 19.4 (24.8) 19.6 (23.7) 
3 yr avg death CV dz 106.5 
(90.0) 
113.2 (96.8) 119.3 
(101.3) 
107.0 
(91.7) 
112.7 (105) 108.7 (93.7) 
County Median Hhld 
income (1000’s) 
44.6 (9.4) 45.1 (9.6) 46.6 (10.2) 43.5 (9.6) 44.7 (10.0) 44.7 (10.5) 
Unemployment rate 5.2 (1.4) 5.4 (1.5) 5.5 (1.7) 10.7 (2.1) 10.7 (2.1) 10.5 (2.3) 
Notes: *Inclusion in AF treatment group conditional on value of zero for this variable. ()=standard deviation 
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Table 4. Estimated Marginal Effects of Policy Changes, Patient Characteristics 
and Inpatient Facility Characteristics on OAT initiation  
 Adjusted for Patient 
Characteristics 
Adjusted for Patient and Facility 
Characteristics 
Unadjusted Results     
Guideline Positive -0.05    
Guideline Negative -0.02    
Intervention   0.05    
Adjusted Results     
Post Period -0.04
*
 (-0.07,-0.01) -0.03
*
 (-0.06,-0.00) 
Treatment Group -0.39
***
 (-0.43,-0.35) -0.38
***
 (-0.42,-0.34) 
Post*Treatment  0.10
**
 (0.04,0.17)  0.11
**
 (0.04,0.18) 
Post*Gldln Negative -0.03 (-0.19,0.13) -0.03 (-0.19,0.13) 
Patient Characteristics     
18-40yrs  0.03 (-0.03,0.09)  0.03 (-0.02,0.09) 
61-70yrs -0.01 (-0.04,0.02) -0.01 (-0.04,0.02) 
71+years -0.10
***
 (-0.13,-0.07) -0.10
***
 (-0.14,-0.07) 
Gender (Male)  0.02
*
 (0.00,0.04)  0.03
**
 (0.01,0.05) 
Charlson(0)  0.01 (-0.03,0.06)  0.01 (-0.03,0.05) 
Charlson(2) -0.04
*
 (-0.07,-0.00) -0.04
*
 (-0.07,-0.00) 
Charlson(3-4) -0.02 (-0.06,0.03) -0.01 (-0.06,0.03) 
Charlson(5-11) -0.13
***
 (-0.17,-0.09) -0.12
***
 (-0.17,-0.08) 
CHADS2(0-1) -0.02 (-0.05,0.02) -0.01 (-0.05,0.03) 
CHADS2(3-4) -0.05
*
 (-0.09,-0.01) -0.04
*
 (-0.08,-0.00) 
CHADS2(5-6) -0.04 (-0.11,0.04) -0.03 (-0.10,0.04) 
Rural  0.02 (-0.03,0.06)  0.01 (-0.05,0.07) 
Micropolitan  0.01 (-0.03,0.04) -0.00 (-0.05,0.04) 
0 Pre-Event Visits -0.05
*
 (-0.09,-0.00) -0.04 (-0.09,0.00) 
2+ Pre-Event Visits  0.06
***
 (0.03,0.09)  0.05
***
 (0.02,0.08) 
Facility Characteristics     
Primary Stroke Center   -0.01 (-0.06,0.04) 
GWTG participation   -0.01 (-0.03,0.02) 
4-99 beds   -0.04 (-0.09,0.00) 
500+ beds   -0.04 (-0.08,0.00) 
25+ miles   -0.10
***
 (-0.16,-0.05) 
Rural provider    0.07 (-0.01,0.16) 
Micropolitan Provider    0.04 (-0.01,0.09) 
Observations 5235  5235  
95% confidence intervals in parenthesis  
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
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Table 5. Estimated Marginal Effects of Sensitivity Analyses in Alternate Outcome 
Definitions, Outpatient Only Cohort and Combined Inpatient/Outpatient Cohorts 
 OAT-RX & OAT-Labs OAT-Labs OAT-Outpatients OAT-ALL 
18-40yrs 0.01 (-0.04,0.07) 0.01 (-0.03,0.06) -0.02 (-0.07,0.03) 0.01 (-0.03,0.04) 
61-70yrs -0.02 (-0.04,0.01) -0.18
***
 (-0.21,-0.14) 0.02 (-0.01,0.06) 0.01 (-0.02,0.04) 
71+years -0.12
***
 (-0.16,-0.09) -0.38
***
 (-0.43,-0.34) -0.05
*
 (-0.09,-0.01) -0.09
***
 (-0.11,-0.06) 
Gender 
(Male) 
0.02 (-0.00,0.04) 0.01 (-0.01,0.03) 0.06
***
 (0.03,0.08) 0.04
***
 (0.02,0.06) 
Charlson(0) 0.02 (-0.02,0.06) 0.03 (-0.00,0.05) 0.03 (-0.01,0.07) 0.01 (-0.01,0.04) 
Charlson(2) -0.03 (-0.06,0.01) -0.02 (-0.05,0.01) -0.04 (-0.08,0.01) -0.05
**
 (-0.08,-0.01) 
Charlson (3-4) -0.00 (-0.05,0.04) -0.04
*
 (-0.07,-0.00) -0.05 (-0.09,0.00) -0.05
**
 (-0.08,-0.01) 
Charlson(5-
11) 
-0.12
***
 (-0.16,-0.07) -0.07
***
 (-0.11,-0.03) -0.11
***
 (-0.17,-0.05) -0.13
***
 (-0.17,-0.09) 
CHADS2(0-1) -0.00 (-0.04,0.04) 0.02 (-0.01,0.05) 0.02 (-0.02,0.06) 0.00 (-0.03,0.03) 
CHADS2(3-4) -0.04
*
 (-0.08,-0.00) -0.01 (-0.03,0.02) -0.01 (-0.05,0.03) -0.03
*
 (-0.05,-0.00) 
CHADS2(5-6) -0.02 (-0.08,0.04) -0.04 (-0.10,0.02) -0.04 (-0.10,0.03) -0.04 (-0.09,0.01) 
Rural -0.00 (-0.07,0.06) -0.04
*
 (-0.08,-0.01) -0.05 (-0.11,0.01) -0.03 (-0.07,0.01) 
Micropolitan -0.01 (-0.06,0.04) -0.03
**
 (-0.05,-0.01) 0.00 (-0.05,0.05) -0.01 (-0.04,0.02) 
Post Period -0.02 (-0.05,0.01) 0.03
**
 (0.01,0.05) 0.01 (-0.02,0.04) -0.01 (-0.03,0.01) 
Treatment 
Group 
-0.38
***
 (-0.42,-0.34) -0.14
***
 (-0.18,-0.10) -0.44
***
 (-0.50,-0.39) -0.42
***
 (-0.46,-0.38) 
Post*Treatme
nt 
0.09
*
 (0.02,0.16) 0.03 (-0.03,0.09) 0.17
***
 (0.09,0.25) 0.14
***
 (0.08,0.19) 
Guideline 
Negative 
-0.44
***
 (-0.53,-0.36) -0.21
***
 (-0.27,-0.15) -0.49
***
 (-0.64,-0.34) -0.49
***
 (-0.57,-0.40) 
Post*Gldln 
Negative 
-0.03 (-0.19,0.13) -0.02 (-0.11,0.08) 0.09 (-0.10,0.29) 0.02 (-0.10,0.14) 
0 Pre-
diagnosis 
Visits 
-0.05
*
 (-0.09,-0.00) -0.06
***
 (-0.10,-0.03) 0.09
**
 (0.03,0.14) 0.02 (-0.01,0.06) 
2+ Pre-
diagnosis 
Visits 
0.05
***
 (0.02,0.08) 0.04
***
 (0.02,0.07) 0.08
***
 (0.04,0.12) 0.06
***
 (0.03,0.08) 
Primary 
Stroke Center 
-0.01 (-0.06,0.04) -0.02 (-0.05,0.00)     
GWTG 
participation 
-0.01 (-0.04,0.01) -0.00 (-0.03,0.02)     
4-99 beds -0.04
*
 (-0.09,-0.00) 0.01 (-0.02,0.04)     
500+ beds -0.03 (-0.07,0.01) -0.01 (-0.05,0.03)     
25+ miles -0.10
***
 (-0.15,-0.05) -0.04
***
 (-0.06,-0.02)     
Rural provider 0.08 (-0.00,0.17) 0.05 (-0.01,0.10) 0.12
**
 (0.04,0.20) 0.11
***
 (0.05,0.17) 
Micropolitan 
Provider 
0.05
*
 (0.00,0.09) 0.04
*
 (0.00,0.08) 0.01 (-0.04,0.06) 0.04
*
 (0.01,0.07) 
Inpt Index 
Claim 
      -0.03
**
 (-0.05,-0.01) 
Observations 5235  5235  4694  9380  
95% confidence intervals in parentheses  
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
 
 
Chapter 3 
 
THE EFFECT OF GEOGRAPHIC, PHYSICIAN, FACILITY, AND PATIENT FACTORS ON 
ORAL ANTICOAGULATION INITIATION AND DISCONTINUATION  
 
Overview 
 
 Although some barriers to anticoagulation for patients with atrial fibrillation are 
known, little is known concerning their overlap with determinants of time to anticoagulation 
discontinuation or how initial inpatient versus outpatient diagnosis influences them. We 
identified a cohort of incident atrial fibrillation patients using five years of claims data. Based 
on this and other linkable data sources, we measured: patient, provider, and geographic 
characteristics; diagnosis setting; and anticoagulation therapy initiation and time to 
discontinuation in a prospective new-user design study. We implemented generalized linear 
models and survival analysis methods to examine barriers to initiation, determinants of time 
to discontinuation and overlap between them. We identified a total of 7,748 incident atrial 
fibrillation patients, of which 2,146 (28%) initiated anticoagulation therapy. Initial diagnosis 
setting was not associated with initiation or time to discontinuation. Older age at diagnosis 
was associated with lower initiation (0.7% per year 95% CI -0.8% to -0.6%) and a lower 
hazard of discontinuation (HR 0.66 95% CI 0.42-0.85). Men had greater initiation (OR=1.25 
95% CI 1.08-1.35) and greater hazard of discontinuation (HR=1.09 95% CI 0.99-1.20). 
Greater number of comorbidities at diagnosis was associated with lower initiation and 
greater hazard of discontinuation. Within one year 1,167 (54%) patients discontinued 
therapy, and 63% of them did not restart during the observation period. Too few patients 
initiate OAT and among those that do, many discontinue therapy quickly. The potential 
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stroke risk reduction of anticoagulation therapy is mitigated by its underutilization and early 
discontinuation among eligible individuals.  
Introduction 
 Oral anticoagulation therapy (OAT) to reduce acute ischemic stroke risk in moderate 
or high risk atrial fibrillation (AF) patients, typically with Warfarin, has been recommended by 
guidelines from major organizations for nearly two decades [66]. However, despite its 
benefit, OAT is often underutilized among eligible AF patients [86,87,75,76]. This 
underutilization may be secondary to low rates of OAT initiation or precipitous OAT 
discontinuation.  
 Barriers to OAT initiation exist at the level of patients, physicians and health care 
systems (see Table 6) [23,61,62,88,29,78,89,39,72,90,80].  In contrast, determinants of 
OAT discontinuation and the extent of their overlap with barriers to OAT initiation are not as 
well documented, with notable exceptions summarized in Table 6. Higher stroke risk and 
age >65 years at OAT initiation are inversely associated with OAT discontinuation [85,91]. 
Male gender [85,69] poor cognitive function [92], poverty [93], higher educational attainment 
[92], and homelessness [94] have been associated with OAT discontinuation.  
 Recent years demonstrate a growing trend of initial diagnosis and management for 
incident AF in the outpatient setting [95,96]. It is not known how this shift away from an 
inpatient initial diagnosis setting may influence barriers to OAT initiation or determinants of 
discontinuation. Additionally, changes in the healthcare system such as revision of The Joint 
Commission National Patient Safety Goals (NPSG) to include anticoagulation and the 
emergence of the patient centered medical home (PCMH) may increase or attenuate 
potential differences in OAT initiation by initial diagnosis setting (i.e., inpatient versus 
outpatient). We sought to: examine the influence of initial diagnosis setting on barriers to 
OAT initiation, corroborate and expand predictors of OAT discontinuation, and determine the 
degree of overlap, if any, with barriers to OAT initiation in patients with incident AF.  
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Methods 
 
Data Source   
 Data came from the North Carolina State Health Plan (NCSHP), a large self-funded 
insurance plan. NCSHP includes almost 1 million state employees, teachers, retirees and 
their dependents. Retired non-Medicare participants and retired Medicare beneficiaries 
compose 10% and 15% of the plan respectively. This claims database contains inpatient, 
outpatient and pharmacy records. Fields include encrypted member identification numbers, 
age, gender, county, and zip code of member residence. Records include diagnoses, 
procedures, providers, charges and payments. The database also contains provider level 
characteristics which include zip code, type of provider and specialty if applicable. We linked 
individual and hospital/practice counties with additional variables from the Area Resource 
File which allowed us to examine patient, provider, and county characteristics. 
 
Procedures 
 We used NCSHP data from January 1, 2006-December 31, 2010 to examine OAT 
initiation and persistence during two time periods -- before (January 2006-December 2008) 
and after (January 2009-December 2010) NPSG revisions.  For both periods, patients 
needed to be continuously enrolled in the NCSHP a minimum of 6 months prior to and a 
minimum of 6 months following the qualifying index claim. Individuals with a prescription 
claim for Warfarin more than 30 days prior to an index claim were excluded due to a high 
probability of representing prevalent rather than incident AF.  
We used either one inpatient diagnosis or two outpatient diagnoses within 12 months 
(ICD-9-CM code 427.31) to identify individuals with new onset AF. Cohort entry date was 
defined as either the first outpatient AF claim or the inpatient admission date. CHADS2 is a 
commonly employed scoring system to evaluate stroke risk and benefit from OAT [81] that 
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can be generated from claims data (See Appendix Table A3.1 for ICD-9-CM codes). We 
included all individuals meeting criteria for incident AF with a CHADS2 score > 2. Finally, to 
reduce the probability of including individuals with prevalent AF we excluded individuals with 
any AF-related claim in the six months preceding the index claim. 
 
Measures  
 Our key dependent variables were OAT initiation (a prescription claim for Warfarin 
within 30 days of index AF claim) and OAT discontinuation (greater than 60 days without 
Warfarin coverage by prescription claims).  
 Explanatory variables of interest were initial AF diagnosis setting (inpatient versus 
outpatient) and receipt of care in a PCMH (1 or more outpatient claims from a provider in a 
PCMH) in the 30 days preceding the index claim. We created control variables at the 
patient, provider, and county level. To mitigate potential confounding, all control variables 
were measured in the baseline period or immediately prior to the index AF claim [97]. 
Patient level control variables include age, gender, Charlson Comorbidity Index [98] 
(categorized as 0,1-2,3+), CHADS2 score [81] (categorized as 2,3-4,5
+), rural/urban 
residence, and number of outpatient visits to a primary care provider in the 30 days prior to 
the index claim. Rural/Urban status was categorized as metropolitan, micropolitan or rural as 
defined by the Area Resource File [82]. Median county household income, unemployment 
rate, number of office based general practitioners per county, health professional shortage 
area (HPSA), number of office based cardiovascular specialists per county and the 3 year 
average number of deaths from cerebrovascular disease were also from the Area Resource 
File.  
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Propensity Score Implementation 
 To reduce possible confounding with medical home enrollment, we used propensity 
scores to balance the two groups on pre-treatment covariates.  We estimated, conditional on 
baseline covariates, an individual’s probability of receiving care in a medical home in the 30 
days before the index event. In our models we included variables associated with OAT 
initiation, based on theory or prior evidence, and potentially associated with medical home 
status [99]. To estimate the propensity score, we employed generalized boosted regression 
with an iterative algorithm that optimized covariate balance based on average standardized 
absolute mean difference (ASAMD) [100].  We then used stabilized inverse-probability-of-
treatment weights (IPTW) to estimate the average treatment effect [101].   
Statistical Analysis 
 We examined characteristics of eligible AF patients by OAT initiation status and then 
compared patient characteristics by the setting in which the initial diagnosis was made. In 
multivariable analysis, we used a generalized linear model with a log link, Poisson 
distribution and robust clustered standard errors. This model accounted for within-facility 
correlation among practices and hospitals. We then re-estimated the model for inpatients 
and outpatients separately, followed by a generalized Hausman test to compare effects. We 
present marginal effects (absolute risk differences) for ease of interpretation. 
 To examine discontinuation, we implemented a repeated events analysis using the 
Prentice, Williams, Peterson-Gap time approach to account for multiple periods of OAT 
initiation and persistence. We then performed non-parametric tests for differences in hazard 
of discontinuation by individual covariates. We created smoothed hazard functions for each 
covariate to visually assess for violations of the proportional hazards assumption. We then 
implemented a Cox proportional hazards model, clustered at the individual level to account 
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for multiple OAT use periods and stratified by AF diagnosis year.  Following model 
specification and optimizing covariate functional form, we formally tested for violations to the 
proportional hazards assumption globally and for each covariate. All models were estimated 
in Stata 11. (StataCorp, College Station, TX) 
 
Sensitivity Analysis 
 We conducted several sensitivity analyses to assess sensitivity to alternate 
definitions of OAT initiation, OAT discontinuation and PCMH engagement. To examine OAT 
initiation we used the ICD-9 CM code for anticoagulation management (V58.61) and 
procedure codes for corresponding blood tests (CPT codes: 99363, 99364, 85610, 85730 
and, 85732) within 30 days of index event to create a non-pharmacy claims OAT initiation 
definition. To maximize sensitivity, a third OAT initiation definition combined the pharmacy 
claim and non-pharmacy claims definitions (positive if either of these two definitions were 
positive).  
 We then examined the length of time without Warfarin required to indicate OAT 
discontinuation. We used 30, 90, 120, 150 and 180 days without Warfarin by pharmacy 
claims to define OAT discontinuation in addition to our primary 60 day definition.  
 We examined variations in defining PCMH engagement based upon the percentage 
of all primary care visits to a PCMH 30 days preceding the index event. We used 30% and 
50% thresholds for two additional definitions of PCMH engagement.  
 Finally, we performed the time to discontinuation analysis in a competing events, or 
cause specific framework, in which death was included as a competing event to 
discontinuation. 
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Results 
Characteristics of Patients 
 OAT initiators were on average 3.5 years younger, slightly more likely male, and had 
marginally lower number of exclusions, Charlson comorbidity index, and CHADS2 scores 
(Table 7). They were also slightly less likely to receive an initial AF diagnosis in an inpatient 
setting. OAT initiators had similar numbers of outpatient visits in the baseline period as non-
initiators but resided a shorter distance from their provider. Although statistically different, 
the OAT initiators came from counties with approximately similar unemployment rates and 
median household incomes. Distribution of rural/urban and HPSA status was similar for both 
groups. Finally, the number of office based general internists and cardiovascular specialists 
practicing in the county was similar in both groups.  
 Patients with an initial inpatient diagnosis were on average 2.2 years older, slightly 
more likely female, and had a marginally higher Charlson comorbidity index (Table 8). 
Number of relative exclusions from OAT and CHADS2 score was similar between the 
groups. Patients with an initial inpatient diagnosis were less likely to initiate OAT (26.1% vs. 
29.2% p<.003). Initial inpatients had on average one less visit in the baseline period (3.5 vs. 
4.4 p<.001) but were similar to initial outpatients in the distribution of rural/urban status 
HPSA status and numbers of office based general internists and cardiovascular specialists.  
Associations with OAT Initiation and Discontinuation 
 Average marginal effects for OAT initiation are shown in Table 9. Column 1 displays 
the aggregate model, while column 2 and 3 represent models for initial inpatients only and 
initial outpatients only. Each additional year of age at initial diagnosis reduced the probability 
of OAT initiation by 0.69%. That is, a five year increase in age at time of diagnosis was 
associated with a 3.45% decrease in the probability of OAT initiation. Medical home 
enrollment and male gender were associated with an increase in the probability of OAT 
initiation, while an increasing number of relative exclusions to OAT, increasing Charlson 
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comorbidity score, and increasing CHADS2 score were associated with a decreased 
probability of OAT initiation in the aggregate model. Median household income and 
unemployment rate of the patients’ county were weakly positively associated with OAT 
initiation.  Patients residing in metropolitan and micropolitan counties were slightly less likely 
to initiate OAT than patients residing in rural counties. HPSA status, initial inpatient status, 
and diagnosis in 2009-2010 were not associated with OAT initiation.  
 Average marginal effects for the inpatient and outpatient subsets were generally 
similar with two notable exceptions. Male patients were more likely to initiate OAT as 
outpatients than as inpatients (6.5%, 95% CI 2 to 11%). Increasing CHADS2 score was 
associated with a lower probability of OAT initiation for outpatients (-2.7%, 95% CI -0.65% to 
-4.7%) but not for inpatients.  
 Median aggregate time to discontinuation was 289 days after index event. Times 
were similar for diagnosis setting (301 days vs. 275 days) and medical home engagement 
(287 days vs. 297 days).  Results from the time to event analysis are displayed in Table 10. 
Older age at diagnosis was associated with a lower hazard for OAT discontinuation. Male 
gender was weakly associated with discontinuation. Increasing Charlson score and number 
of individual relative exclusions to receiving OAT were associated with a greater hazard for 
OAT discontinuation. However, CHADS2 score was not associated with time to OAT 
discontinuation. Outpatient visits in the baseline period, initial inpatient diagnosis and PCMH 
engagement were also not associated with time to OAT discontinuation.  
Sensitivity Analysis 
 Our multiple sensitivity analyses (see appendix material) were not qualitatively 
different from our primary analyses presented here. Changes in the definition of OAT 
initiation marginally increased the percentage of OAT initiators as expected, but did not 
change the average marginal effects substantially for our first analysis. Increasing the 
number of days without Warfarin required indicating discontinuation reduced the number of 
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OAT periods observed in our data but did not substantially influence our hazard ratio 
estimates for time to OAT discontinuation. Some estimates were less significant with the 
observed reduction in sample size. Changes in the definition of PCMH engagement 
decreased the number of patients with PCMH engagement, but did not substantially change 
the average marginal effects of our estimates. Finally, our competing events analysis was 
essentially identical to our cumulative incidence analysis. We observed only 34 competing 
events in comparison to 2,225 failures.  
 
Discussion 
 The prevalence of AF in an aging US population is increasing. Availability of new 
anticoagulants and efforts to deliver more patient-centric coordinated care hold 
transformative potential but remain largely untested in clinical practice. These trends, 
combined with a shift towards greater outpatient diagnosis and management, provide 
rationale for reevaluating OAT initiation and discontinuation. Within this context we sought to 
examine the influence of initial diagnosis setting on OAT initiation and discontinuation while 
controlling for previously identified barriers to initiation and predictors of discontinuation. 
Among observational studies, our work exhibits several relative strengths which include: a 
large stable insured population across the state of North Carolina; a five year time period; 
analysis of only incident AF; the merged nature of our data; controlling for a number of 
relative exclusions to OAT; and analysis in a state with a robust PCMH movement.  
Barriers to OAT initiation: Consistent with prior literature, we found increasing age, 
increasing number of relative OAT exclusions, and increasing Charlson score were 
associated with a lower probability of OAT initiation. For these individuals risks associated 
with OAT may outweigh potential benefits. Initial diagnosis setting was not associated with 
OAT initiation. While in some respects this finding is reassuring as more diagnosis happens 
in the outpatient setting, however overall rates of OAT initiation remained low (27.7%) 
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suggesting continued underuse among AF patients. Somewhat surprisingly in sub-analysis, 
increasing CHADS2 score was not associated with OAT initiation for initial inpatients but was 
strongly negative for outpatients. Lower outpatient initiation for individuals with high CHADS2 
scores may reflect competing co-morbidities and risk of death, unobserved provider barriers 
or unobserved differences in treatment preferences among these patients.  
 Determinants of discontinuation: Consistent with prior work, we found increasing age 
associated with a reduced hazard of discontinuation. Thus age is a determinant for initiation 
and discontinuation, decreasing OAT initiation yet also decreasing discontinuation. Similarly 
male gender is associated with greater probability of initiation but greater OAT 
discontinuation.  
Our 56% one year OAT discontinuation rate is substantially greater than that 
observed in trials (8-12%) [102-104] and reported in observational studies (26-30%) [85,91]. 
We did not attempt to determine whether this high discontinuation rate reflects: a rational 
clinical evaluation of ongoing risks and benefits associated continuing OAT; a change in 
patient preference concerning treatment; unobserved barriers; or clinical practice oversight. 
We believe at minimum it reflects the need for development of decision tools (similar to 
existing initiation decision tools) to evaluate persistence or discontinuation of OAT. They 
should incorporate new knowledge regarding severity of risks and benefits of OAT [105] as 
well as cumulative patient experience with OAT. We do not believe our observed rate of 
discontinuation can be wholly explained by adverse events such as intracranial hemorrhage 
and gastrointestinal bleeding associated with OAT. Annual rates of major bleeding in clinical 
trials are 3-4% per year [102-104]. If discontinuation is primarily a result of major bleeding, 
rates of major bleeding in our study would be 6.5 times that reported in trials or 19-26% per 
year. We find it unlikely that the level of discontinuation in our results is driven primarily by 
adverse events associated with OAT.    
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 Our study has several limitations. First, we did not examine or adjust for reasons to 
discontinue therapy. However, we do not believe this introduces any substantial bias in our 
initiation results concerning our primary exposure of interest, diagnosis setting. Identification 
and adjusting for adverse events and patient preferences may allow for greater clarity in 
evaluating determinants of OAT persistence, but is difficult with only claims level data. 
Second, because we utilized claims data, we did not have access to the level of 
anticoagulation control during OAT. Some patients may have appropriately discontinued 
OAT (in exchange for an antiplatelet agent) secondary to poor anticoagulation level control. 
This question can only be answered with additional laboratory data not available in claims. A 
third limitation was our relative inability to control for race, ethnicity, education and 
socioeconomic status in this analysis. While we did control for these factors to some extent 
using county level variables, the presence of strong unmeasured confounders associated 
with our measures may over or underestimate their association with OAT initiation and time 
to discontinuation.  A final limitation is that we analyzed data in a state located in the “stroke 
belt” within the southeastern United States [1]. Clinical practice patterns concerning OAT 
initiation and discontinuation may not generalize well to regional variations in clinical 
practice.  
 Our findings suggest OAT remains underutilized via both low OAT initiation and early 
discontinuation, providing a target for improved health care quality and a reduction in stroke 
associated mortality and morbidity. The availability of novel anticoagulants and new models 
of care delivery (e.g. the PCMH) provide opportunities for improvement, but their impact 
needs to be thoughtfully supported.  For example, PCMHs seem to lead to slightly improved 
initiation rates, but can this impact be strengthened?  Why aren’t PCMHs associated with 
decreased discontinuation?  If discontinuation of Warfarin is so high, will novel 
anticoagulants that require less ongoing contact with providers be wise? A greater attention 
to duration of pharmacotherapy is needed to manage chronic conditions, particularly when 
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long-term or life-long indications for pharmacotherapy exist. To facilitate increased 
awareness of risks and benefits associated with ongoing pharmacotherapy we encourage 
the development of decision support tools for clinical decision making for continuing or 
discontinuing current management.  
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Table 6. Factors Influencing OAT Initiation and Time to OAT Discontinuation 
  OAT Initiation OAT Discontinuation 
P
a
ti
e
n
t-
L
e
v
e
l 
Age<50 or Age>85 (-)23, 39, 63,67,68,69,70, 72, 
80, 84, 85, 90 
Age<50 (+)91, 94; Age>65 (-)85, 91,  
Male (+)70, 72 Male (+)85,69, 94 
Non-white race (-)23, 61 Non-white race (-/?) 
Poverty (-)71 Poverty (+)93, 94 
Rural Residence (-)70 Rural Residence (?) 
Higher educational attainment (-)94 Higher educational attainment (+)92, 94 
Prior Stroke, Heart Failure,  
Hypertension (+)23, 63, 69, 71, 72 
Prior Stroke (-)91 
Bleed Risk: Frail, prior ICH, GIB, Falls, 
Renal or Hepatic Impairment (-)23, 63, 64, 69, 
71, 78, 84 
Bleed Risk (?) 
Compliance Concerns: Dementia, 
Severe Mental Illness, Alcoholism (-)23, 71, 
78, 84, 85 
Dementia(+)92, 94 
CHADS2 (measure of stroke risk) (-)
23, 71, 
72, 76 
CHADS2 (measure of stroke risk) (-/+)
76, 
85, 91, 94 
      
P
ro
v
id
e
r-
L
e
v
e
l 
Non-malficience (-)80 Non-malficience (?) 
Clinical Uncertainty (-)23, 39, 80 Clinical Uncertainty (?) 
Burden of monitoring (-)23, 39, 80 Burden of monitoring (?) 
Perceived benefit/risk ratio (-)23, 39, 80, 90 Perceived benefti/risk ratio (?) 
Higher % Medicaid (-)80 Higher % Medicaid (?) 
Greater level of experience (+)63, 64, 80 Greater level of experience (?) 
Number years in practice (+)64, 80 Number years in practice (?) 
Primary care vs. Cardiologist (+/-)39, 61, 72, 
88 
Primary care vs. Cardiologist (?) 
PCMH (?) PCMH (?) 
      
S
y
s
te
m
-L
e
v
e
l Diagnosis Setting (?) Diagnosis Setting (?) 
Lower Hospital Acuity Level (+)64 Hospital Acuity Level (?) 
Community practice vs. Coag clinic (?) Community Practice vs. Coag clinic (?) 
South, West Regions (?) South, West Regions (+)94 
Cost-sharing (?)39 Cost-sharing (+)94 
  
Notes: (?) Represents unexplored or unknown. (+) = Positive Association in literature, (-)= 
Negative Association in literature. 
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Table 7. Patient Characteristics of OAT Initiators and Non-Initiators  
  Overall Non-Initiator OAT Initiator   
   (N= 7,748) (N= 5,602)  (N= 2,146) 
P 
value 
  Mean (Standard Deviation) or %   
Mean Age 76.2 (11.3) 77.2 (11.4) 73.7 (10.6) <0.001 
Percent Male 43.3% 41.3% 48.6% <0.001 
Mean Number relative OAT exclusions 0.5 (0.7) 0.6 (0.8) 0.4 (0.7) <0.001 
Mean Charlson Score 2.2 (1.9) 2.3 (1.9) 2.0 (1.7) <0.001 
Mean CHADS2 Score 3.1 (1.2) 3.2 (1.2) 2.9 (1.1) <0.001 
Percent Initial Inpatient Diagnosis 49% 50.1% 46.2% 0.003 
Mean outpatient visits during baseline 4.0 (5.4) 4.0 (5.5) 3.9 (5.0) 0.53 
Mean distance to outpatient provider 
(miles) 35.2 (135.9) 40.3 (156.7) 23.7 (68.6) 0.002 
Mean County: Median Household Income 
(thousands) 45.1 (9.9) 45.2 (9.9) 45.1 (9.8) 0.64 
Mean County: Unemployment Rate 7.5 (3.1) 7.4 (3.1) 7.8 (3.2) <0.001 
Percent Metropolitan Residence  65.4% 66.1% 63.6%  
Percent Micropolitan Residence   23.2%  23.1%  23.6% 0.03  
Percent Rural Residence  11.4%  10.9%  12.8%   
Percent Entire County Health Professional 
Shortage Area  7.6%  7.8%  7.0%   
Percent Partial County Health Professional 
Shortage Area  58.5%  58.8%  57.8%  0.24 
Percent County Not Health Professional 
Shortage Area  33.9%  33.4%  35.2%   
Mean County: Office based General 
Practice Internists 69.0 (76.2) 69.5 (76.3) 67.6 (75.8) 0.32 
Mean County: Office based Cardiovascular 
Specialists 18.3 (23.7) 18.5 (23.7) 17.9 (23.6) 0.28 
Mean County: 3 yr average deaths 
cerebrovascular disease 110.9 (100.6) 112.1 (101.7) 107.8 (97.8) 0.09 
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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Table 8. Characteristics of AF Patients by Initial Diagnosis Setting 
  Overall  
Initial 
Outpatient 
Initial 
Inpatient 
P 
value  
   (N= 7,748)  (N= 3,952)  (N= 3,796)  
  Mean (Standard Deviation) or %   
Mean Age 76.2 (11.3) 75.1 (11.1) 77.3 (11.4) <0.001 
Percent Male 43.3% 46.4% 40.1% <0.001 
Mean Number relative OAT 
exclusions 0.5 (0.7) 0.5 (0.8) 0.5 (0.7) 0.58 
Mean Charlson Score 2.2 (1.9) 2.1 (1.9) 2.3 (1.9) <0.001 
Mean CHADS 2 Score 3.1 (1.2) 3.1 (1.2) 3.1 (1.2) 0.04 
Percent Initiated Warfarin 27.7% 29.2% 26.1% 0.003 
Mean outpatient visits during baseline 4.0 (5.4) 4.4 (6.1) 3.5 (4.5) <0.001 
Median Index Claim Year 2008 2008 2008 <0.001 
Mean County: Median Household 
Income (thousands) 45.1 (9.9) 45.3 (9.9) 45.0 (9.9) 0.15 
Mmbr Cnty unemployment rate 7.5 (3.1) 7.6 (3.1) 7.3 (3.1) <0.001 
Percent Metropolitan Residence(1) 65.1% 66.0%  64.8%    
Percent Micropolitan Residence (2) 23.2%  21.8%  24.7% 0.002  
Percent Rural Residence (0) 11.4%  12.3%  10.5%   
Percent Entire County Health 
Professional Shortage Area  7.6%  7.3%  7.9%   
Percent Partial County Health 
Professional Shortage Area  58.5%  59.5%  57.5%  0.19 
Percent County Not Health 
Professional Shortage Area  33.9%  33.2%  34.6%   
Mean County: Office based General 
Practice Internists 69.0 (76.2) 69.8 (76.9) 68.2 (75.4) 0.34 
Mean County: Office based 
Cardiovascular Specialists 18.3 (23.7) 18.6 (23.7) 18.1 (23.7) 0.31 
Mean County: 3 yr average deaths 
cerebrovascular disease 110.9 (100.6) 111.1 (101.7) 110.7 (99.5) 0.86 
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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Table 9. Average Marginal Effects for Oral Anticoagulation Therapy Initiation  
 Aggregate Model Initial Inpatients Initial Outpatients 
       
Age -0.0069
***
 (-0.0079,-0.0060) -0.0088
***
 (-0.010,-0.0073) -0.0050
***
 (-0.0065,-0.0035) 
PCMH 0.071
***
 (0.045,0.097) 0.078
***
 (0.033,0.12) 0.065
**
 (0.020,0.11) 
Male 0.031
**
 (0.0100,0.052) -0.0052 (-0.039,0.029) 0.064
***
 (0.029,0.098) 
Relative OAT 
Exclusions 
-0.037
***
 (-0.053,-0.021) -0.036
**
 (-0.062,-0.011) -0.039
**
 (-0.065,-0.012) 
Charlson 
Score 
-0.014
***
 (-0.021,-0.0069) -0.017
**
 (-0.028,-0.0057) -0.010 (-0.022,0.0015) 
CHADS2 
Score 
-0.012
*
 (-0.023,-0.0011) 0.0017 (-0.016,0.020) -0.027
**
 (-0.047,-0.0065) 
Median 
Household 
Income 
0.0016
*
 (0.00017,0.0031) 0.00042 (-0.0018,0.0027) 0.0026
*
 (0.00032,0.0049) 
Unemployme
nt Rate 
0.0075
*
 (0.00071,0.014) 0.0068 (-0.0040,0.017) 0.0085 (-0.0023,0.019) 
1 Outpatient 
Baseline Visit 
0.00012 (-0.036,0.036) 0.0090 (-0.044,0.062) -0.0066 (-0.061,0.048) 
2
+
 Outpatient 
Baseline 
Visits  
0.032
*
 (0.0036,0.060) 0.027 (-0.016,0.070) 0.037 (-0.0070,0.081) 
Metropolitan  -0.053
*
 (-0.094,-0.012) -0.056 (-0.12,0.0092) -0.053 (-0.12,0.012) 
Micropolitan  -0.045
*
 (-0.089,-0.00087) -0.049 (-0.12,0.018) -0.045 (-0.11,0.023) 
Whole County 
HPSA 
-0.021 (-0.077,0.036) -0.030 (-0.094,0.034) -0.012 (-0.084,0.061) 
Partial County 
HPSA 
-0.019 (-0.041,0.0025) -0.023 (-0.061,0.014) -0.015 (-0.055,0.024) 
Initial 
Inpatient 
-0.0019 (-0.026,0.022)     
Diagnosed  
2009-10 
0.016 (-0.025,0.057) -0.0049 (-0.071,0.061) 0.033 (-0.031,0.097) 
N 7746  3796  3952  
95% confidence intervals in parentheses. 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Table 10. Patient Characteristics and Hazard of OAT discontinuation 
 Hazard Ratio 95% Confidence Interval  
Age 41-60 years  0.669
*
 (0.45,0.99) 
Age 61-70 years   0.598
**
 (0.41,0.88) 
Age 71+ years  0.647
*
 (0.44,0.95) 
PCMH  0.929 (0.81,1.06) 
Initial Inpatient 1.071 (0.98,1.17) 
Male 1.089 (0.99,1.20) 
Charlson Score    1.055
**
 (1.02,1.09) 
Number relative exclusions     1.204
***
 (1.09,1.33) 
CHADS2 Score 1.012 (0.96,1.06) 
Median Household Income 1.005 (1.00,1.01) 
1 Outpatient Visit Baseline 1.112 (0.95,1.30) 
2+ Outpatient Visits Baseline 1.009 (0.90,1.13) 
Rural  1.131 (0.97,1.32) 
Micropolitan 1.002 (0.89,1.13) 
County Not HPSA 0.954 (0.80,1.14) 
Partial County HPSA 0.929 (0.78,1.11) 
N 3087  
95% confidence intervals in parentheses. 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
THE EFFECT OF PATIENT CENTERED MEDICAL HOMES ON INITIATION OF ORAL 
ANTICOAGULATION THERAPY  
Overview  
Multiple barriers to oral anticoagulation therapy (OAT) for eligible atrial fibrillation 
patients exist within the current healthcare system. Patient-centered medical homes 
(PCMHs) are intended to increase access, quality and value through coordinating more 
holistic patient-centered care, which may reduce these barriers and increase OAT initiation. 
Our objective was to estimate the effect of receiving care in an accredited PCMH on OAT 
initiation for newly diagnosed eligible atrial fibrillation patients compared to conventional 
care. We utilized a retrospective cohort new user design with two comparison groups (2006-
2010). Our population studied was privately insured patients in North Carolina with incident 
atrial fibrillation, mechanical heart valve, significant venous embolism or paroxysmal atrial 
fibrillation. OAT initiation and PCMH exposure were our key dependent and independent 
variables. We developed propensity scores for PCMH exposure followed by inverse 
probability of treatment weighting and estimated effects with generalized estimating 
equations. We found a positive association between PCMH exposure and percentage of 
patients initiating OAT in both unadjusted (Average Marginal Effect 6.78% p<.001) and fully 
adjusted (6.25% p<.001) models that was robust to variation in defining both PCMH 
exposure and OAT initiation. Males (6.7% p<.001) and individuals with access to care 
(4.88% p<.001), operationalized as those with greater than 2 outpatient visits 90 days before 
the index event, were also associated with greater OAT initiation. PCMH exposure is 
associated with greater OAT initiation for eligible individuals with incident atrial fibrillation.
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However, the effect size is modest and the specific mechanism or mechanisms contributing 
to this effect remain undetermined.   
Introduction  
Acute stroke is the 4th leading cause of death [106].  Patients with atrial fibrillation 
(AF) have an average 5-fold increase in ischemic stroke risk [12] that increases with age 
from 1.5% in individuals ages 50-59 to 23.5% for those ages 80-89 [107,108]. Moreover, 
severity, disability, mortality and frequency of stroke recurrence are greater with AF 
associated stroke [5,4,6]. Since the first randomized clinical trial found that Warfarin reduced 
stroke risk for patients with AF [109], guidelines from major organizations and professional 
societies have recommended oral anticoagulation therapy (OAT) for AF patients at 
moderate- and high-risk of ischemic stroke [66,110-112]. Yet studies repeatedly report OAT 
underutilization in eligible AF patients [63,67,25,27,28,68,69,29,70,71,21-23,72,73,61,74-
76]. Physician and healthcare system factors contribute to OAT underutilization [71,72,77-
79,39,80]. Physician-level barriers to OAT initiation include: (1) perceiving that the risks 
exceed benefits to patients [63,113-117] (despite physicians frequently underestimating the 
relative stroke risk reduction of OAT and overestimating the risk of adverse events such as 
major gastrointestinal bleeding or intracranial hemorrhage [114]); (2) being unfamiliar with 
guidelines recommending OAT for AF patients with moderate or high risk of ischemic stroke 
[114,115]; and (3) believing that patients will not adhere to OAT [63,114,115]. Healthcare 
system barriers to OAT initiation include poor access to appropriate laboratory facilities for 
necessary blood work, difficulty with provider schedule availability, and difficulty with follow-
up on out of range laboratory values for OAT monitoring and dosage titration [115-117]. 
Physician and healthcare system barriers may be mitigated by patient centered 
medical homes (PCMH). The PCMH is intended to increase access, quality and value by 
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coordinating, patient-centered care to enhance population health [53]. Despite the potential 
of the PCMH, many decision makers and policy makers are awaiting empirical evidence 
supporting its effectiveness. Although there is empirical support for individual components of 
PCMH [52], there is little evidence concerning the ability of PCMH to improve quality and 
health outcomes while reducing costs [53,55-57].  Two recent large PCMH systematic 
reviews found some favorable effects on quality, patient experience, and caregiver 
experience; a few unfavorable effects on costs; and mostly inconclusive results [53,54].  
PCMHs have the potential to address many barriers to OAT initiation including: 
strengthening the therapeutic relationship with a personal physician; enhancing access to 
care; increasing follow-up and monitoring; coordinating care with specialists; and 
emphasizing a commitment to improving quality and patient safety. The National Committee 
on Quality Assurance (NCQA) accredits practices that meet PCMH criteria.  We examined 
whether exposure to an NCQA accredited PCMH is associated with increased OAT initiation 
compared to no PCMH exposure.   
Methods 
 Data Source   
We used data from January 1, 2006-December 31, 2010 from the North Carolina 
State Health Plan (NCSHP), a large self-funded insurance plan administered by Blue Cross 
and Blue Shield of North Carolina.  NCSHP includes almost 1 million state employees, 
teachers, retirees and their dependents. Retired non-Medicare participants and retired 
Medicare beneficiaries compose 10% and 15% of the plan, respectively. This claims-
structured database contains inpatient, outpatient and pharmacy records. Fields include 
unique encrypted member identification numbers, basic demographic information including 
age, gender, county, and zip code of primary residence. Records include diagnoses, 
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procedures, providers, charges and payments. The database also contains provider-level 
characteristics including zip code, type of provider and specialty. We also linked individual 
and facility counties with additional variables from the Area Resource File [82], which 
allowed us to consider patient, provider, and county characteristics concurrently. 
  
 
Study Design 
We created three cohorts of patients: (1) new onset AF patients; (2) guideline 
positive controls, i.e., patients at very high risk of thromboembolism (mechanical heart valve 
and pulmonary embolism); and (3) guideline negative controls, i.e., patients at very low risk 
of thromboembolism (paroxysmal AF). For all three cohorts, patients needed to be 
continuously enrolled in the NCSHP a minimum of 6 months prior to and a minimum of 6 
months following the qualifying index claim. Individuals with a prescription claim for Warfarin 
more than 30 days prior to an index claim for any of the three cohorts were excluded due to 
a high probability of representing prevalent rather than incident conditions. Specific eligibility 
criteria for each cohort are described below. 
New onset AF patients:  We used either one inpatient diagnosis or two outpatient 
diagnoses within 12 months (International Classification of Disease- 9-Clinical Modification 
(ICD-9-CM) code 427.31) to identify individuals with AF. Cohort entry date was defined as 
either the first outpatient AF claim or the date of admission for an inpatient claim. CHADS2 is 
a commonly-used risk-based score [81] that can identify individuals who are most likely to 
benefit from OAT that can be readily generated using claims data (See Appendix Table A3.2 
for ICD-9-CM codes). We included all individuals meeting criteria for incident AF with a 
CHADS2 score > 2. To increase the appropriateness of this cohort, we excluded individuals 
with one or more relative contraindications to receiving OAT (identified using ICD-9-CM 
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codes) from the incident AF or intervention cohort (See Appendix Table A3.3 for 
contraindications and ICD-9-CM codes).  Finally, to reduce the probability of including 
individuals with prevalent AF rather than incident AF we excluded individuals with any AF 
related claim in the six months preceding the index claim.    
Guideline positive controls: We identified individuals with either one inpatient 
diagnosis or two outpatient diagnoses within 12 months indicating a mechanical heart valve 
or significant thromboembolism. Those with at least six months of continuous eligibility prior 
to and six months continuous eligibility following the index claim were included in the 
guideline positive cohort (See Appendix Table A3.4 for diagnoses and ICD-9-CM codes). 
The CHADS2 score was not applied to this cohort, as it is only validated in patients with AF; 
however, individuals with one or more relative contraindications to receiving OAT were 
excluded to increase comparability between cohorts. Finally, to reduce the probability of 
including individuals with prevalent conditions rather than incident mechanical heart valves 
or significant thromboembolism, we excluded individuals with any condition-related claim in 
the six months preceding the index claim. 
Guideline negative controls: We identified individuals with either one inpatient 
diagnosis or two outpatient diagnoses within 12 months for paroxysmal AF (ICD-9-CM code 
427.21). Those with at least six months of continuous eligibility prior to and six months 
continuous eligibility following the index claim were included in the guideline negative cohort. 
Again we excluded individuals with one or more relative contraindications to receiving OAT 
to create cohorts similar in bleeding risk that differed only in their risk of acute ischemic 
stroke. 
 
Measures  
 The dependent variable was OAT initiation, defined by a prescription claim for 
Warfarin within 30 days from AF date of onset.  The exposure of interest was receipt of care 
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in an NCQA-accredited PCMH during the 30 days prior to the index event. We created 
control variables at the patient and provider level. To mitigate potential confounding, all 
control variables were measured in the baseline period or immediately prior to the index AF 
claim. Patient level control variables include age, gender, Charlson comorbidity Index 
(categorized as 0, 1-2, and ≥3), CHADS2 score (categorized as 2, 3-4, and ≥ 5), rural/urban 
residence (metropolitan, micropolitan or rural [82]), and number of outpatient visits to a 
primary care provider in the 30 days prior to the index claim. Provider level control variables 
included Rural/Urban location and a binary variable indicating participation with the North 
Carolina Medicaid’s medical home program [118].  
 
Propensity Score Implementation 
 To reduce possible confounding with PCMH exposure, we used propensity scores to 
balance the two groups on pre-treatment covariates.  We estimated, conditional on baseline 
covariates, an individual’s probability of receiving care in a PCMH during the 30 days prior to 
the index event. In our propensity score models, we included variables that, based on prior 
theory or evidence, were associated with OAT initiation or OAT initiation and PCMH status 
[99]. To estimate the propensity score, we employed generalized boosted regression using 
the “twang” package in R (Version 2.15.1). This package uses an iterative algorithm to 
construct multiple classification and regression trees, leading to selection of a model that 
optimizes covariate balance based on the average standardized absolute mean difference 
across covariates [100].  We then used stabilized inverse-probability-of-treatment weights 
(IPTW) to estimate the average treatment effect [101].   
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Statistical Analysis 
 To estimate the association between PCMH exposure and OAT initiation within each 
cohort, we utilized a generalized estimating equation model with a Poisson distribution, log 
link, and exchangeable within-group correlation structure. We grouped at the practice level 
using practice identification fields in the database. This model accounted for within-practice 
correlation of outcomes among the accredited PCMH and non-PCMH practices across 
separate individuals. We estimated average marginal effects (absolute risk differences) for 
ease of interpretation. All models were estimated in Stata 11. (StataCorp, College Station, 
TX) 
Sensitivity Analysis 
  
 We first examined variations in the definition of OAT initiation. To test and compare 
with our OAT initiation definition based on pharmacy claims, we created a second non-
pharmacy claims definition of OAT initiation. The second definition used ICD-9 CM codes for 
anticoagulation management and procedures codes for corresponding blood tests within 30 
days of index event (See Appendix Table A3.5). A third definition of OAT initiation was a 
combination of the first two; positive if either of the first two definitions were positive. Next, 
we examined variations in the definition of PCMH exposure based upon the percentage of 
all primary care visits in the 30 days prior to index event that were to a PCMH. We used 
30% and 50% thresholds for these two additional definitions of PCMH exposure.  
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Results 
Descriptive 
 Baseline characteristics of the AF (n=4,424), guideline positive (n=6,530) and 
guideline negative cohorts (n=618) following IPTW are presented in Table 11. Standardized 
differences between PCMH users and non-PCMH users for each cohort are also shown. 
Standardized difference was below the suggested threshold of 10% for all variables in both 
the AF and the guideline positive cohorts, indicating sufficient baseline covariate balance by 
PCMH status. However, the guideline negative cohort contained multiple baseline 
covariates that remained above the 10% threshold in absolute standardized mean difference 
following optimized generation of propensity scores and IPTW [119]. This cohort was also 
quite small in comparison to the other cohorts. Thus, although we report data for this cohort, 
we are cautious in interpreting the results. The AF cohort had a greater mean age and 
Charlson comorbidity index score than the guideline positive cohort. The proportion of males 
in the guideline negative cohort was greater than the AF and guideline positive cohorts. The 
number of pre-index outpatient visits was highest in the guideline positive cohort. The 
distribution of individuals by geographic residence, health professional shortage areas, 
generalist and specialist availability, and year of entry into the cohort was comparable 
among the three cohorts.   
Multivariable Results 
 Multivariable adjusted results are consistent with unadjusted bivariate results (top of 
Table 12) for exposure to an NCQA PCMH.  Model 1 for each cohort adjusts for patient 
characteristics, location of residence, use of health care in the baseline period, and year of 
cohort entry. Model 2 adjusts for the aforementioned characteristics and additional practice 
characteristics. Unadjusted and adjusted estimates for Model 1 and Model 2 of the effect of 
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PCMH use on OAT initiation are comparable for both the AF (6-7%) and guideline positive 
(14%) cohorts. In other words, patients exposed to an NCQA accredited PCMH were 6-7 
percentage points more likely to initiate OAT than patients not exposed to an NCQA 
accredited PCMH. 
Examining the adjusted results in more detail, men were more likely to initiate OAT in 
the AF cohort, but equally as likely to initiate OAT in the guideline positive cohort. Charlson 
comorbidity scores decreased the likelihood of initiating therapy only in the highest 
comorbidity category for the AF cohort, while the guideline positive cohort exhibited 
decreasing initiation in a stepwise fashion. Increasing CHADS2 scores were unexpectedly 
associated with a lower likelihood of initiating OAT for the AF cohort, while increasing 
CHADS2 scores had no effect on OAT initiation for the guideline positive cohort. Rural 
residence appeared to be associated with a slight increase in the likelihood of initiating OAT 
but this effect was mitigated when we controlled for practice location (rural, micropolitan, 
metropolitan). We also discovered a higher than anticipated positive association between 
rural practice location and OAT initiation in both the AF and guideline positive cohorts. More 
than two outpatient visits in the 90 days preceding the index event was also associated with 
an increased likelihood of OAT initiation. We found a strong positive time association with 
initiating OAT in the AF cohort that was not observed (as expected) in the guideline positive 
cohort. Finally practice participation in the North Carolina Medicaid medical home program 
was weakly suggestive of a positive association with OAT initiation in both AF and guideline 
positive cohorts.  
Sensitivity Analysis 
 Results of sensitivity analyses are presented in Table 13. We implemented the fully 
adjusted models (Model 2) in these analyses, but report only the average marginal effect of 
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PCMH use on OAT initiation here. Generally, the average marginal effect of PCMH on OAT 
initiation was robust to alternative definitions of OAT initiation and PCMH status. Model 1 in 
each cohort reflects the first alternative definition of OAT initiation as defined by ICD-9-CM 
anticoagulation management codes and blood lab tests. The second model in each cohort 
reflects the second alternative definition of OAT initiation, either a positive original definition 
or a positive first alternative definition. Finally, after returning to the original OAT initiation 
definition the third and forth models represent the previously described 30 percent and 50 
percent thresholds respectively. The magnitude of the association decreases with increasing 
sensitivity and decreasing specificity of the OAT initiation measure, but in all cases remains 
positive. Similarly varying the definition of PCMH user resulted in a smaller magnitude 
positive association of PCMH with OAT initiation.   
Discussion 
Despite evidence-based guidelines, OAT initiation rates are low for patients with AF. 
Along with the rise of Accountable Care Organizations, PCMHs hold potential for improving 
OAT initiation for AF patients. We examined the effect of receiving care in an NCQA 
accredited PCMH on OAT initiation among incident AF patients. The study and analysis 
have several notable strengths. The data represent a large, stable, insured population 
across the entire state of North Carolina during 5 years of observation, allowing us to 
implement a new user type study design with comparison groups. The merged aspect of the 
data including provider, practice, and county level variables also strengthens the analysis. 
Second, we perform this analysis in a state that has a well-documented and robust PCMH 
movement. During the observation period, North Carolina had more accredited PCMHs than 
any other state except New York. This critical mass of PCMHs resulted in an analysis that 
included more than 100 independent PCMHs, far more than any other analysis known to us. 
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This heterogeneity allows a greater generalizability to the PCMH experience as a whole 
rather than the selected experience of a few PCMHs.   
We found a modest increase in OAT initiation associated with PCMH exposure for 
patients with incident AF as well as the guideline positive comparison cohort. The effect 
sizes are within plausible ranges for both cohorts, but are somewhat larger for the guideline 
positive comparison group. We hypothesize several possible explanations for these findings. 
First, as noted above, there are numerous provider and healthcare system barriers to OAT 
initiation. It may be that the PCMH only partially mitigated these barriers, and the effect of 
some barriers may have been less substantial for the younger guideline positive cohort. 
Second, our results may reflect greater use of OAT in PCMHs regardless of the indication. 
The practices that become accredited PCMHs may be more likely to prescribe OAT either 
because of geographic location, previous practice patterns or patient preference. In this 
case, PCMH accreditation status may serve as a proxy for practices inclined towards OAT 
use. Given the breadth of scope and principles of the PCMH model, we believe this 
explanation unlikely. Finally, practices with PCMH accreditation may reflect higher quality 
practices or practices that are more predisposed to practice pattern change at baseline. 
Ultimately we believe our findings represent a mixture of the first and third explanations. 
PCMH status does appear associated with modest increasing OAT initiation in eligible AF 
patients and the guideline positive comparison group that may result from PCMH status 
reflecting higher baseline quality or partial implementation of all components in the PCMH 
model.  
The positive time trend associated with OAT initiation in only the AF cohort also 
merits discussion. We believe this finding represents, in part, an external trend towards 
increasing OAT initiation in eligible AF patients, which may reflect response to The Joint 
Commission’s revised National Patient Safety Goals for anticoagulants [38]. However, the 
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trend begins before these revisions were publicly announced in 2008. A second reason for 
the observed positive time trend of OAT initiation in the AF cohort could relate to anticipated 
availability of novel anticoagulants that were not yet approved for use in AF. Knowledge of 
these novel oral anticoagulants poised to enter the market circulated among clinicians as 
early as 2006. The first of these agents did not ultimately reach the market for use in AF 
until late 2010, but this interest may have resulted in greater awareness and willingness to 
prescribe OAT for eligible AF patients. How the availability of these novel oral 
anticoagulants will influence OAT initiation in these patients and by PCMH practice status is 
an area of great interest to us.  
There are several limitations of our study. First, because we used insurance claims 
data, we may have misclassified OAT initiation.  This is especially true because the 
popularity of low-cost generic prescription drug programs may lead to patients filling 
prescriptions for OAT without billing the insurer [83]. If this were to occur, we would have 
underestimated the rate of OAT initiation in both cohorts regardless of PCMH status. 
However, we have no reason to suspect a differential error in pharmacy claims for Warfarin 
with respect to the cohorts or PCMH status regarding OAT initiation. Moreover, because we 
control for time in our models, we would have expected this trend, decreasing OAT initiation 
in later years, to appear in the year indicators. However, we find the opposite trend in our 
year indicators, suggesting this effect is small or non-existent. Importantly, our sensitivity 
analyses suggested that findings were robust to alternative definitions of OAT initiation.  
Second, we could not directly control for patient’s race, ethnicity or socioeconomic status, 
though we did control for county level indicators of race and socioeconomic status. Finally, 
our cohorts were predominantly individuals with employee sponsored group health 
insurance and the results may not generalize to publicly insured populations. Notably, our 
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cohorts included a large proportion of retired Medicare enrollees utilizing both their Medicare 
and NCSHP benefits, which serves to enhance generalizability to Medicare beneficiaries.  
Despite the noted limitations, our findings suggest that PCMH status is associated 
with greater OAT initiation among eligible AF patients.  However, this effect may increase or 
decrease in time secondary to continued refinement of the PCMH model and the availability 
of novel oral anticoagulants. Future investigations of PCMHs and OAT initiation will be of 
great interest with respect to the changes in delivery of care and the real-world effectiveness 
of these agents.  
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Table 11. Baseline Characteristics Following Inverse Probability of Treatment Weighting For Each 
Cohort 
  Atrial Fibrillation Cohort Positive Comparison Group 
Negative Comparison 
Group 
Covariate 
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference  
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference  
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference 
  (N=466) (N=3,957) % (N=863) (N=5,667) % (N=69) (n=549) % 
Age 76.3 76.2 0.70% 63.2 64.4 7.10% 68.3 67.8 3.60% 
Charlson 1.85 1.87 1.20% 1.47 1.61 7.80% 1.71 1.72 0.50% 
CHADS2 
Score 2.83 2.87 3.30% 1.91 2.02 6.80% 2.06 1.96 7.50% 
Male 0.42 0.45 4.80% 0.39 0.41 4.40% 0.59 0.63 7.10% 
Pre Index 
Visits 3.52 3.45 1.40% 4.58 4.97 5.30% 3.6 3.59 0.10% 
Metropolitan 66.90% 64.90% 
6.70% 
70.80% 66.30% 
3.10% 
63.77% 67.05% 
13.20% 
Micropoltan 24.10% 23.06% 22.50% 23.80% 27.39% 21.71% 
HPSA –No 32.60% 35.30% 
6.40% 
31.40% 33.90% 
6.40% 
30.14% 35.17% 
10.70% 
HPSA – 
Yes 6.90% 8.00% 6.40% 7.50% 7.67% 7.65% 
HPSA - 
Partial 60.39% 56.70% 62.20% 58.50% 62.75% 57.21% 
#GPs 70.3 65.5 6.20% 77.7 71.6 7% 79.74 71.2 10.70% 
#CV 
Specialist 19 17.5 6.50% 21 19.1 7% 22.4 19.2 12.70% 
Dth_CV_DZ 111.12 107.71 3.40% 118.9 114.4 3.90% 123.98 113.28 10.50% 
2006 15.00% 18.40% 
6.30% 
12.60% 15.80% 
8% 
9.42% 13.33% 
7.70% 
2007 26.90% 25.40% 20.70% 21.00% 19.93% 25.66% 
2008 20.90% 21.10% 20.60% 20.90% 32.17% 20.46% 
2009 19.90% 19.10% 24.30% 21.50% 23.91% 23.59% 
2010 17.30% 16.00% 21.90% 20.80% 15.07% 16.99% 
 Notes: Std=Standardized, HPSA = Health Professional Shortage Area, GPs = Number of office based general 
practitioners in county. CV Specialist = Number of office based cardiovascular specialists in county, Dth_CV_DZ = 3 
year average number of cerebrovascular (stroke) deaths in county.  
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Table 12. Unadjusted Difference in Percent OAT Initiation & Average Marginal Effect of 
Explanatory Variables in Three Cohorts  
  Atrial Fibrillation Cohort 
Positive Comparison 
Group 
Negative Comparison 
Group 
Covariate 
Unadjusted 
Estimate 6.78%*** 
Unadjusted 
Estimate 14.4%*** 
Unadjusted 
Estimate 6.53% 
  Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
Medical Home User  7.04%***  6.25%***  14.71%***  13.95%***  11.67%**   9.98%** 
Age 18-40  
(referent group 41-60) 
-3.89%    -1.75%  -1.67%  -2.21% -14.51%* -14.7%** 
Age 61-70  3.15%  4.29%*  -2.04%  -2.01%  12.91%***  15.1%*** 
Age 71+ -1.68% -1.41%  -7.69%***  -8.19%***   5.17%   5.53% 
Male  6.67%***  6.70%***   1.63%    1.80%  15.48%***  15.33%** 
Charlson 0 
(referent group Charlson 
1) 
-0.55% -0.02%   4.97%**   5.03%**   0.13%  -0.9% 
Charlson 2 -1.05% -0.82%  -6.07%***  -5.79%**  -4.84%  -4.5% 
Charlson 3-4 -2.02% -1.43%  -6.09%***  -5.87%**  -5.85%  -5.71% 
Charlson 5-12 -8.63%*** -8.54%*** -14.59%*** -14.07%*** -11.04%** -12.86%** 
CHADS2 3-4 
(referent group CHADS2 
2) 
-4.14%** -4.26%**    0.74%   1.36%  -5.06%  -7.13% 
CHADS2 5-6 -5.44%* -5.31%*  -1.05%  -0.96%   4.73%  -7.49% 
Rural (referent group 
Metropolitan) 
 4.17%* -1.59%   4.23%**  -1.52%  -4.36%  -3.43% 
Micropolitan  2.6% -0.22%   2.05%  -3.73%**   4.83%   4.64% 
Zero prior visits 
(referent group 1 prior 
visit) 
 1.53%  1.92%  -6.0%***  -5.15%**   7.28%   7.84% 
2+ prior visits  5.19%***  4.88%***   6.73%***   7.17%***  12.36%**  12.14%** 
Year=2007 
(referent group 2006) 
10.82%*** 11.04%***   0.66%   1.21%  18.04%*** 18.12%*** 
Year=2008 13.35%*** 13.43%***   0.66%   0.52%  -1.4%  -1.81% 
Year=2009 15.77%*** 16.94%***  -2.42%  -2.25%   6.45%   7.18% 
Year=2010 12.86%*** 13.10%***  -0.91%  -0.84%  10.05%*   9.22% 
Rural Practice (referent 
group Metropolitan) 
  10.98%***    12.4%***    -8.18% 
Micropolitan Practice    4.3%     9.93%***    -0.87% 
CCNC Practice     3.96%*     3.12%     5.78% 
N  4,423 4,423 6,530 6,530 610 610 
CCNC = Community Care North Carolina (Medicaid Medical Home member) 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001  
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Table 13. Sensitivity Analysis 
  Atrial Fibrillation Cohort Positive Comparison Group Negative Comparison Group 
  Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
MH30D 7.07%*** 3.08%**   13.90%*** 8.76%***   8.17% 10.87%***   
MH30P     4.05%**     4.55%**     11.51%*** 
MH50P     3.96%*     4.99%**     13.39%*** 
 Notes: MH30D = PCMH visit within 30 days of index event; MH30P = 30% of primary care visits to PCMH in initial 
90 days following index event; MH50P = 50% of primary care visits to PCMH in initial 90 days following index 
event. 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001  
 
 
Chapter 5  
CONCLUSIONS 
Summary of Findings 
 Each of these three studies provides unique opportunities for synthesis of new 
information, practice implications, policy implications and suggest additional research 
questions to be answered. The studies as a whole, however, provide a larger narrative than 
the sum of their individual parts. In general, we sought to: develop a greater understanding 
of barriers to OAT initiation, determinants of OAT discontinuation and areas of overlap 
between these two events; and to what extent observed policy and practice changes may 
have influenced the use of OAT via their influence on these two events. Here, I will discuss 
five over-arching strategic concepts that frame the broader meta-narrative of this research 
effort.  
 First, I found that policy and practice change levers do appear to create sufficient 
alterations in the external healthcare system that foster modest changes in the receipt and 
provision of care. These changes may be in the provision of guideline concordant care such 
as an increasing rate of OAT initiation among incident AF patients appearing eligible for 
OAT as indicated by claims data. The changes may also be a reduction in inappropriate 
care such as the reduction in the rate of OAT initiation among incident paroxysmal atrial 
fibrillation patients appearing ineligible for OAT as indicated by claims data. I saw these 
changes specifically in the revision of the NPSG by The Joint Commission in 2008 to include
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standard safety practices and guidelines concerning the use of OAT as an example of a 
policy lever. This policy lever provided incentives for change in hospitals and other 
healthcare organizations via a potential loss of Medicare reimbursement in the event of non-
compliance or failure to achieve Joint Commission accreditation. I presented the PCMH as 
an example of a practice change lever. Patients with incident AF who appeared eligible for 
OAT as indicated by claims and who received care in a PCMH accredited by the National 
Committee on Quality Assurance (NCQA) had a higher rate of OAT initiation than patients 
not receiving care in an accredited PCMH. I posit that the incentives to undergo the 
necessary accreditation by NCQA and the process changes required to become a PCMH 
are currently generally positive incentives (i.e. greater market share, greater reimbursement, 
etc). Thus it would appear that irrespective of the positive or negative incentives for 
modification, both polarities of incentives can provide sufficient motivation by participants to 
do so. Because the policy and practice levers are not directly comparable, I cannot speak to 
the relative magnitude of effect between policy and practice levers and the changes in 
provision of care. I do want to note that these observed changes were for relatively short-
term measures usually requiring a point-in-time decision such as OAT initiation. However, I 
did not find strong evidence to support policy and practice levers’ ability to generate 
changes in longer term measures typically requiring more sustained effort such as time to 
OAT discontinuation. 
 Second, I learned that the inclusion of positive and negative control groups or 
nonequivalent dependent variables is imperative in observational research using claims 
data. For example, I expected a 95% OAT initiation rate for individuals with newly implanted 
mechanical heart valves and serious systemic thromboembolism such as a pulmonary 
embolism. However I found a substantially lower “observed” rate of OAT initiation in this 
population. I believe this reflects a limitation in using claims data rather than the failure to 
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provide appropriate care. In other words, this observed level of OAT initiation for the 
strongest known indication for OAT was only 65%. I would not expect to find a greater rate 
of OAT initiation for a population with a “relatively weaker” indication for OAT, such as AF. 
This finding alone provides much needed context for many prior observational studies using 
claims involving OAT use among individuals with AF.  More study is needed to validate an 
“appropriate” rate of observed OAT initiation among eligible incident AF individuals in claims 
data.    
 The third strategic concept that emerged as a result of this interrelated body of work 
reflects the measurement of provision and receipt of care for long-term or life-long indicated 
therapies. I gained a greater understanding of the complexity involved in measuring receipt 
of care for therapies that have long-term or life-long indications. Population health 
concerning chronic conditions requires more than an emphasis on initiation of appropriate 
therapy alone. It also includes a focus on the maintenance of that therapy for an extended 
period of time. This duration of therapy might be termed persistence, or as I refer to it in this 
work, time to discontinuation. In fact these concepts of initiation and duration of therapy (e.g. 
maintenance, persistence, time to discontinuation) appear to be two unique concepts. These 
concepts share some overlapping predictors or determinants that at times work in the same 
direction and at times in opposing directions (See Table 14 below). For example, a greater 
number of comorbidities at time of diagnosis and a greater number of relative OAT 
exclusions were associated with both a lower rate of OAT initiation and a greater hazard of 
OAT discontinuation. Initiation and duration of therapy may also have non-overlapping 
factors which we need to identify as well. Receipt of care in a PCMH and CHADS2 score 
were both correlated with OAT initiation but not associated with time to OAT discontinuation. 
There is a need to sharpen the way we think about these concepts when we as health 
services researchers study these interventions and their outcomes.  
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 Fourth, I was initially surprised by my findings that increased stroke risk, as indicated 
by a claims implemented CHADS2 score at the time of AF diagnosis was paradoxically 
associated with a lower OAT initiation rate and a greater hazard of discontinuation. I can 
identify several distinct possible explanations for these findings. Despite a rigorous review of 
prior literature validating the CHADS2 score as a measure of stroke risk among patients with 
AF, there may be problems with the implementation of this score using claims data [81,120]. 
Others have utilized the CHADS2 score with claims data and have reported findings 
consistent with these findings [121,37].  Or perhaps the CHADS2 score functions as a low 
hurdle to overcome for OAT initiation but at higher CHADS2 scores, other comorbidities 
present serve to outweigh potential benefits of therapy. Despite sufficient risk of stroke 
secondary to AF, other concurrent disease processes with a high probability of death 
mitigate the potential benefits of receiving OAT. Finally, these findings do not account for 
patient preference or knowledge which is integral to studying both therapy initiation and time 
to therapy discontinuation [122].  
 The fifth and final strategic concept I wish to convey relates to study design. To be 
consistent with a new user study design, I constructed the PCMH engagement variable as a 
baseline measurement that occurred in a 30 day window immediately prior to the index 
event. This operationalization of PCMH engagement is equivalent to an intent-to-treat 
analysis in a randomized controlled trial. However, the real world is not a randomized 
controlled trial. People change treatment arms, or do not accept the treatment they are 
randomized to receive. Crossover in treatment arms within a randomized controlled trial can 
lead to an averaging of effects, which may also be considered a bias towards a null effect. It 
is possible that this occurred in this study as well. While the results are encouraging with 
respect to OAT initiation and PCMH engagement, I realize that in some aspects, an “as 
treated analysis” may give us more real world information. I was reminded that researchers 
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should always be mindful of the type of treatment effect they want to measure and to ask if it 
is appropriate for the research question they are trying to answer. 
Limitations 
 As with any study or body of work, there are limitations, and this work is not an 
exception to that rule. I want to acknowledge and discuss the implications of these 
limitations. First I will review several general limitations that are common to all three aims. 
Then I will discuss and review several limitations specific to individual studies. 
  This study utilizes claims level data. While robust in nature, it does not perfectly 
convey the truth of what actually happened in any particular situation. Identification of AF, 
concurrent comorbid conditions, OAT initiation, and subsequent time to OAT discontinuation 
are subject to misclassification. I acknowledge that claims data does not reflect in all cases 
complete fidelity to the gold standard of a patient’s medical record. However, I believe on 
the whole, it is a reasonable proxy for studying relative differences in OAT initiation over 
time.  
 Second, I did not have access to individual level race, ethnicity, income or, education 
data in this work. Prior literature has demonstrated that these are important factors in OAT 
initiation [23,61,29,78,89,39,72,123]. Similarly, poverty and educational attainment have 
been associated with OAT discontinuation [92,93].  I did however attempt to control for 
these factors to some degree with county level measures of race, ethnicity, and income. The 
inability to completely control for these factors at the individual level has several potential 
implications. While I do not believe the aggregate results are substantially influenced, I may 
overlook possible heterogeneity of treatment effect with respect to the key independent 
variables and specific subpopulations defined by race, ethnicity, income and, education 
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level. I was also unable to identify potential intervention targets with respect to these 
subpopulations.  
 The third broad limitation refers to the study sample. These studies examined a 
privately insured population in NC from 2006-2010. I acknowledge the regional variation 
inherently present in clinical practice and cannot claim that clinical practice by providers in 
North Carolina reflects the spectrum of clinical practice within the United States as a whole. I 
believe the study sample does generalize well to the population of North Carolina. However, 
attempts to generalize it to publicly insured populations such as Medicaid or Medicare or 
outside this state should be approached with caution. With this in mind, I observed a large 
number of Medicare eligible and Medicare receiving individuals in this study, and I don’t 
have prima fascia reasons to believe this population would not generalize to other states.  
 There are several study specific limitations to mention as well.  
Study 1 
  I know aggregate OAT initiation rate for the population of individuals diagnosed with 
incident AF both before and after a policy level was introduced. However, I do not know 
which hospitals had well developed OAT policies in place before the guidelines, or if (and 
when) they subsequently modified their policies to achieve compliance with the revised 2008 
NPSG. Moreover, I do not know which hospitals created policies where none previously 
existed, and when they did so. This does not affect the overall estimates of effect of the 
policy, but does limit the ability to examine specific hospitals and the exact mechanism of 
change.     
Study 2  
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 I did not attempt to examine or adjust for clinical reasons to discontinue OAT. 
Because both risks and benefits exist with this therapy, from a clinical perspective there are 
several valid reasons for discontinuation. If a known adverse event of therapy such as 
severe bleeding (i.e. intracranial hemorrhage or gastrointestinal bleed) occurs with a patient, 
it may be appropriate to discontinue OAT either temporarily or permanently.  Similarly, I did 
not adjust for the percentage of time a patient was within an optimal therapeutic level (e.g. 
INR=2-3) of anticoagulation while receiving OAT. Therefore, in the instance of an extremely 
small percent of time spent within optimal therapeutic level of anticoagulation, a provider 
may appropriately opt to discontinue OAT and switch to another less effective but also 
potentially less harmful therapy. I was not able to identify these individuals in our data. Thus 
the results may overestimate the percentage of people with AF who discontinue OAT and 
receive no stroke risk reduction therapy.   
Study 3 
  As was briefly mentioned in the synthesis of findings, this study was an intent-to-treat 
analysis based upon PCMH exposure during the baseline period. I did not examine the 
amount of crossover between treatment assignment arms. It is possible that crossover 
between treatment arms is approximately equal in which crossover at worst biases results 
towards a null effect. However when unequal crossover between treatment groups occurs, it 
is more difficult to anticipate the expected direction and magnitude of the biases introduced. 
While I believe the results are robust in small to moderate amounts of crossover, I recognize 
the possibility that large degrees of unobserved treatment crossover may alter the findings. 
In the future I will repeat this study, quantify the magnitude of crossover and implement an 
as treated analysis to establish greater real world practice relevance.  
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Practice Implications, Policy Implications and Future Directions 
 The one year rate of OAT discontinuation was substantially higher in this study than 
has previously been reported both in trials and other observational studies. While I 
acknowledge that OAT discontinuation is somewhat sensitive to the definition of 
discontinuation, the underlying observation is substantial regardless. Because I utilize 
claims data rather than patient medical records, it is unclear if this high discontinuation rate 
reflects: a rational clinical evaluation of ongoing risks and benefits associated with 
continuing OAT; a change patient preference with respect to continuing OAT; unobserved 
barriers in receipt of medical care; or clinical practice oversight. Undeniably, the unobserved 
factors associated with OAT discontinuation require further elucidation. However, I believe 
at minimum the findings reflect the need for development of clinical decision support tools 
(similar to existing initiation clinical decision support tools) to facilitate a systematic clinical 
decision making process in the persistence or discontinuation of OAT. These tools should 
incorporate new knowledge regarding severity of risks and benefits of OAT [105] as wells as 
cumulative patient experience with OAT. To maximize clinical practice value, the tools 
should also incorporate additional concurrent but unrelated potential for morbidity and 
mortality secondary to the presence of multiple co-occurring chronic conditions. 
 In the post health care reform era, much of health care policy is centered upon 
quantifying, measuring and delivering high quality care. A current metric frequently utilized is 
the receipt of guideline concordant care. As health policy analysts and researchers attempt 
to define receipt of guideline concordant care across a multitude of conditions to measure 
care quality, we encourage consideration of duration of appropriate therapy in addition to 
initiation of appropriate therapy. This consideration is particularly germane when considering 
non-acute chronic conditions with long-term or life-long indications for treatment.  
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Summary  
 Policy and practice change in health care can improve the delivery of health care and 
subsequently the quality and length of human life. In this body of work, I utilized 
observational methods to gain a greater understanding of barriers to OAT initiation, 
determinants of OAT discontinuation, areas of overlap between them and to what extent 
observed policy and practice changes influenced the use of OAT via their influence on 
initiation and discontinuation. I then reviewed several strategic concepts that emerged as a 
result of the synthesis of three separate but related studies. I also discussed global and 
specific limitations of these studies and their implications concerning my primary findings. 
Finally, I briefly identified relevant implications of my findings for practice, policy and 
avenues of future research. 
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Table 14. Factors Influencing OAT Initiation and Time to OAT Discontinuation 
  OAT Initiation OAT Discontinuation 
P
a
ti
e
n
t-
L
e
v
e
l 
Increasing Age(-) Age>40 (-) 
Male (+) Male (+) 
Non-white race (-) Non-white race (-/?) 
Poverty (-) Poverty (+) 
Rural Residence (+) Rural Residence (0/+) 
Higher educational attainment (-) Higher educational attainment (+) 
Prior Stroke, Heart Failure,  
Hypertension (+) 
Prior Stroke (-) 
Bleed Risk: Frail, prior ICH, GIB, Falls, 
Renal or Hepatic Impairment (-) 
Bleed Risk: Frail, prior ICH, GIB, Falls, 
Renal or Hepatic Impairment (+) 
Compliance Concerns: Dementia, 
Severe Mental Illness, Alcoholism (-) 
Dementia(+) 
Increasing Comorbidities (-) Increasing Comorbidities (+) 
CHADS2 (measure of stroke risk) (-) CHADS2 (measure of stroke risk) (0/+) 
      
P
ro
v
id
e
r-
L
e
v
e
l 
Non-malficience (-) Non-malficience (?) 
Clinical Uncertainty (-) Clinical Uncertainty (?) 
Burden of monitoring (-) Burden of monitoring (?) 
Perceived benefit/risk ratio (-) Perceived benefti/risk ratio (?) 
Higher % Medicaid (-) Higher % Medicaid (?) 
Greater level of experience (+) Greater level of experience (?) 
Number years in practice (+) Number years in practice (?) 
Primary care vs. Cardiologist (?) Primary care vs. Cardiologist (?) 
PCMH (+) PCMH (0/-) 
      
S
y
s
te
m
-L
e
v
e
l Inpatient Diagnosis Setting (0) Inpatient Diagnosis Setting (0/+) 
Rural Hospital (+) Hospital Acuity Level (?) 
Community practice vs. Coag clinic (?) Community Practice vs. Coag clinic (?) 
South, West Regions (?) South, West Regions (+) 
Cost-sharing (?) Cost-sharing (+) 
  
 Notes: Bolded factors represent factors and associated relationships between OAT initiation 
and discontinuation explored in this work. (?) Represents unexplored or unknown. (+) = 
Positive Association, (-)= Negative Association, (0)=No association in published literature 
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Appendix One: CHAPTER 2 SUPPLEMENTAL MATERIAL 
Table 15. ICD-9-CM Codes and Drug Class Codes Employed to Assign CHADS2 
Stroke Risk Score 
Condition Classification Codes used to identify condition 
Congestive Heart 
Failure 
ICD-9-CM 425.4, 428.x, 429.4 
Hypertension ICD-9-CM 362.11, 401.x-405.xx, 437.2 
Diabetes Mellitis ICD-9-CM 250.xx, 357.2, 362.0x, 366.41 
Prior 
thromboembolism 
ICD-9-CM 
325, 362.3x, 410.xx, 411.1, 411.81, 415.1x, 
433.xx-434.xx, 435.x 436, 437.1, 437.6, 444.xx, 
451.xx 452, 453.x 
ICD-9-CM = International classification of Diseases, Ninth Revision, Clinical Modification 
 
Table 16. ICD-9CM Codes Utilized to Identify Relative Exclusions to OAT   
Heart Valves 
394.XX, 395.XX, 396.XX, 397.XX, 398.90 424.XX, 093.2X, V42.2, 
V43.3 
Hemorrhagic 
Stroke 
430.XX, 431.XX, 432.XX, 852.0X, 852.2X, 852.4X, 853.XX 
Gastrointestinal 
or other major 
bleed 
286.0X, 286.1X, 286.2X, 286.3X, 286.4X, 287.1X, 287.8X, 287.9X, 
456.0X, 530.21, 530.7X, 530.82, 531.00, 531.01, 531.20, 531.40, 
531.41, 531.60, 531.61, 532.00, 532.01, 532.20, 532.21, 532.40, 
532.41, 532.60, 532.61, 533.00, 533.01, 533.20, 533.21, 533.40, 
533.41, 533.60, 533.61, 534.00, 534.01, 534.20, 534.21, 534.40, 
534.41, 534.60, 534.61, 535.01, 535.11, 535.21, 535.31, 535.41, 
535.51, 535.61, 537.83, 569.85, 569.86, 596.7X, 626.2X 
Fall Risk 
332.0X, 333.4X, 333.5X, 333.90, 333.99, 334.XX, 335.XX, 340.XX, 
345.1X, 345.3X, 345.4X, 345.5X, 345.7X, 345.8X, 345.9X, V15.88 
E880-E888 
Cirrhosis 
570.XX, 571.2X, 571.3X, 571.5X, 571.6X, 571.8X, 571.9X, 572.2X, 
572.3X, 572.4X, 572.8X 
Compliance 
291.XX, 292.1X, 292.8X, 295.03, 295.04, 295.13, 295.14, 295.23, 
295.24, 295.33, 295.34, 295.43, 295.44, 295.53, 295.54, 295.63, 
295.73, 295.74, 295.83, 295.84, 295.93, 295.94, 297.XX, 298.XX, 
V15.81, V60.1, V60.2, V60.3, V60.4 
Dementia 290.XX 
Terminal 
150.XX, 151.XX, 155.XX, 156.XX, 157.XX, 162.XX, 172.XX, 183.XX, 
191.XX, V66.7 
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Table 17. ICD-9CM and CPT Codes Utilized to Identify Guideline Positive Cohort 
Heart Valve 
Replacement 
33405, 33406, 33407, 33408, 33409, 33410, 33411, 33412, 33413, 
33430, 33465, 33475, V42.2, V43.3 
Embolism 
415.12, 415.13, 415.19, 416.2X, 425.11, 453.2X, 453.3X, 453.4X, 
453.5X, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.79, 453.82, 
453.83, 453.84, 453.85, 453.86, 453.87, 453.89, 453.9X 
 
Table 18. ICD-9-CM / CPT codes to identify laboratory blood tests and 
anticoagulation management  
ICD-9-CM Code V58.61  
CPT Code 99363, 99364, 85610, 85730, 85732  
 
 
 
Table 19. Model Specification and Average Marginal Effect of Post_TrtGrp 
 (1) (2) (3) (4) (5) 
 LN Cat AGE Age_NoBed CatNoBed 
Post* 
TrtGrp 
0.11
**
 
[0.04,0.18] 
0.11
**
 
[0.04,0.18] 
0.11
**
 
[0.04,0.18] 
0.11
**
 
[0.04,0.18] 
0.11
**
 
[0.04,0.18] 
N 5235 5235 5235 5235 5235 
95% confidence intervals in brackets 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001
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Appendix Two: CHAPTER 3 SUPPLEMENTAL MATERIAL 
Table 20. ICD-9-CM Codes and Drug Class Codes Employed to Assign CHADS2 Stroke 
Risk Score 
Condition Classification Codes used to identify condition 
Congestive Heart 
Failure 
ICD-9-CM 425.4, 428.x, 429.4 
Hypertension ICD-9-CM 362.11, 401.x-405.xx, 437.2 
Diabetes Mellitus ICD-9-CM 250.xx, 357.2, 362.0x, 366.41 
Prior 
thromboembolism 
ICD-9-CM 
325, 362.3x, 410.xx, 411.1, 411.81, 415.1x, 433.xx-
434.xx, 435.x 436, 437.1, 437.6, 444.xx, 451.xx 452, 
453.x 
ICD-9-CM = International classification of Diseases, Ninth Revision, Clinical Modification 
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Appendix Three: CHAPTER 4 SUPPLEMENTAL MATERIAL 
 
Table 21. Baseline Characteristics (Unadjusted) 
  Atrial Fibrillation Cohort Positive Comparison Group Negative Comparison Group 
Covariate 
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference  
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference  
Medical 
Home 
Non-
Medical 
Home 
Std 
Difference 
  N=466 N=3,957 % N=863 N=5,667 % N=69 n=549 % 
Age 75.2 76.3 9.00% 61.0 65.1 26.30% 69.6 67.7 14.40% 
Charlson 1.91 1.87 2.70% 1.41 1.66 14.10% 1.75 1.72 2.00% 
CHADS2 
Score 2.88 2.87 1.20% 1.78 2.08 18.30% 2.16 1.95 15.90% 
Male 0.41 0.45 8.30% 0.40 0.41 2.30% 0.55 0.63 16.90% 
Pre Index 
Visits 4.6 3.32 27.00% 5.69 4.92 9.90% 4.37 3.43 18.00% 
Metropolita
n 75.00% 63.39% 
7.40% 
79.41% 63.86% 
12.90% 
75.27% 65.47% 
6.70% 
Micropolta
n 16.35% 24.18% 14.46% 25.58% 19.35% 22.48% 
HPSA –No 26.28% 36.44% 
28.80% 
21.65% 36.05% 
38.50% 
22.58% 35.97% 
33.10% 
HPSA – 
Yes 2.72% 8.64% 3.10% 8.33% 5.38% 8.09% 
HPSA – 
Partial 70.99% 54.92% 75.25% 55.62% 72.04% 55.94% 
#GPs 95.9 61.3 45.00% 102.2 66.1 42.70% 96.3 68 36.90% 
#CV 
Specialist 27 16 44.50% 28 17 42.10% 27 18 37.20% 
Dth_CV_D
Z 141.15 102.91 38.90% 146.32 108.45 32.30% 140.55 109.63 31.60% 
2006 8.97% 19.61% 
30.00% 
11.68% 16.51% 
15.70% 
8.60% 13.85% 
18.80% 
2007 22.44% 25.65% 17.65% 21.52% 16.13% 26.26% 
2008 25.48% 20.73% 22.71% 20.50% 33.33% 19.78% 
2009 22.12% 18.63% 26.31% 20.76% 23.66% 23.02% 
2010 20.99% 15.38% 21.65% 20.69% 18.28% 17.09% 
Notes:  Std=Standardized, HPSA = Health Professional Shortage Area, GPs = Number of office based general 
practitioners in county. CV Specialist = Number of office based cardiovascular specialists in county, Dth_CV_DZ = 3 year 
average number of cerebrovascular (stroke) deaths in county.  
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Table 22. ICD-9-CM Codes and Drug Class Codes Employed to Assign CHADS2 
Stroke Risk Score 
Condition Classification Codes used to identify condition 
Congestive Heart 
Failure 
ICD-9-CM 425.4, 428.x, 429.4 
Hypertension ICD-9-CM 362.11, 401.x-405.xx, 437.2 
Diabetes Mellitus ICD-9-CM 250.xx, 357.2, 362.0x, 366.41 
Prior 
thromboembolism 
ICD-9-CM 
325, 362.3x, 410.xx, 411.1, 411.81, 415.1x, 
433.xx-434.xx, 435.x 436, 437.1, 437.6, 444.xx, 
451.xx 452, 453.x 
ICD-9-CM = International classification of Diseases, Ninth Revision, Clinical Modification 
 
Table 23. ICD-9CM Codes Utilized to Identify Relative Exclusions to OAT   
Heart Valves 
394.XX, 395.XX, 396.XX, 397.XX, 398.90 424.XX, 093.2X, V42.2, 
V43.3 
Hemorrhagic 
Stroke 
430.XX, 431.XX, 432.XX, 852.0X, 852.2X, 852.4X, 853.XX 
Gastrointestinal 
or other major 
bleed 
286.0X, 286.1X, 286.2X, 286.3X, 286.4X, 287.1X, 287.8X, 287.9X, 
456.0X, 530.21, 530.7X, 530.82, 531.00, 531.01, 531.20, 531.40, 
531.41, 531.60, 531.61, 532.00, 532.01, 532.20, 532.21, 532.40, 
532.41, 532.60, 532.61, 533.00, 533.01, 533.20, 533.21, 533.40, 
533.41, 533.60, 533.61, 534.00, 534.01, 534.20, 534.21, 534.40, 
534.41, 534.60, 534.61, 535.01, 535.11, 535.21, 535.31, 535.41, 
535.51, 535.61, 537.83, 569.85, 569.86, 596.7X, 626.2X 
Fall Risk 
332.0X, 333.4X, 333.5X, 333.90, 333.99, 334.XX, 335.XX, 340.XX, 
345.1X, 345.3X, 345.4X, 345.5X, 345.7X, 345.8X, 345.9X, V15.88 
E880-E888 
Cirrhosis 
570.XX, 571.2X, 571.3X, 571.5X, 571.6X, 571.8X, 571.9X, 572.2X, 
572.3X, 572.4X, 572.8X 
Compliance 
291.XX, 292.1X, 292.8X, 295.03, 295.04, 295.13, 295.14, 295.23, 
295.24, 295.33, 295.34, 295.43, 295.44, 295.53, 295.54, 295.63, 
295.73, 295.74, 295.83, 295.84, 295.93, 295.94, 297.XX, 298.XX, 
V15.81, V60.1, V60.2, V60.3, V60.4 
Dementia 290.XX 
Terminal 
150.XX, 151.XX, 155.XX, 156.XX, 157.XX, 162.XX, 172.XX, 183.XX, 
191.XX, V66.7 
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Table 24. ICD-9CM and CPT Codes Utilized to Identify Guideline Positive Cohort  
Heart Valve 
Replacement 
33405, 33406, 33407, 33408, 33409, 33410, 33411, 33412, 33413, 
33430, 33465, 33475, V42.2, V43.3 
Embolism 
415.12, 415.13, 415.19, 416.2X, 425.11, 453.2X, 453.3X, 453.4X, 
453.5X, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.79, 453.82, 
453.83, 453.84, 453.85, 453.86, 453.87, 453.89, 453.9X 
 
Table 25. ICD-9-CM / CPT codes to identify laboratory blood tests and 
anticoagulation management  
ICD-9-CM Code V58.61  
CPT Code 99363, 99364, 85610, 85730, 85732  
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